{"Title": ["Anika Therapeutics Inc (ANIK) Q1 2020 Earnings Call Transcript", "Validea Benjamin Graham Strategy Daily Upgrade Report - 3/18/2020", "Anika Therapeutics Beats Revenue and Earnings Estimates", "Anika Therapeutics Inc (ANIK) Q4 2019 Earnings Call Transcript", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 2/16/2020", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 1/19/2020", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 12/15/2019", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 12/15/2019", "Anika Therapeutics Inc (ANIK) Q1 2020 Earnings Call Transcript", "Commit To Buy Anika Therapeutics At $55, Earn 25% Annualized Using Options", "Anika Therapeutics Inc (ANIK) Q3 2019 Earnings Call Transcript", "Why Anika Therapeutics Stock Crushed It Today", "Anika Therapeutics Blows Past Q2 Earnings Estimates", "Anika Therapeutics Inc (ANIK) Q2 2019 Earnings Call Transcript", "Anika Therapeutics Inc (ANIK) Q1 2019 Earnings Call Transcript", "Notable Tuesday Option Activity: OMCL, NOW, ANIK", "Commit To Buy Anika Therapeutics At $55, Earn 25% Annualized Using Options", "Anika Therapeutics (ANIK) Q4 Earnings and Revenues Top Estimates", "Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for", "Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder", "Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead", "ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?", "Anika Therapeutics Enters Oversold Territory", "Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump", "Anika Therapeutics (ANIK) Q4 2018 Earnings Conference Call Transcript", "Anika Therapeutics Inc (ANIK) Q3 2018 Earnings Conference Call Transcript", "Anika Therapeutics (ANIK) Q3 Earnings Beat Estimates", "What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?", "Anika Therapeutics (ANIK) Q3 Earnings Preview: What to Look Out For", "Ultragenyx Reports Top-line Data From Gene Therapy Candidate", "AMAG In-Licenses Global Rights to Orphan Drug Candidate", "Verastem Out-Licenses China Rights to Cancer Drug Copiktra", "ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?", "FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study", "FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program", "Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher", "OPKO Health (OPK) Begins RAYALDEE Phase 2 Clinical Trial", "Sesen Bio (SESN) Soars: Stock Adds 6.3% in Session", "Retrophin (RTRX) Catches Eye: Stock Jumps 6.9%", "Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 8% in Session", "Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate", "Anika Reports Top Line Data from CINGAL Study, Shares Slump", "Why Anika Therapeutics, Inc. Stock Is Sinking", "Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash", "Why Pivotal Software, Anika Therapeutics, and Oracle Slumped Today", "Mid-Afternoon Market Update: NASDAQ Rises 1%; Naked Brand Group Shares Spike Higher", "Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away?", "Notable Thursday Option Activity: ANIK, TREE, COUP", "2 Biotech Stocks That Tanked This Week: Can They Recover?", "New Strong Sell Stocks for April 20th", "New Strong Sell Stocks for April 16th", "New Strong Sell Stocks for April 6th", "New Strong Sell Stocks for April 2nd", "Anika Therapeutics Enters Oversold Territory", "New Strong Sell Stocks for February 27th", "Mid-Morning Market Update: Markets Open Higher; Huntsman Earnings Top Estimates", "Mid-Afternoon Market Update: Dow Turns Positive; Anika Therapeutics Shares Fall Following Disappointing Q1 Results", "Mid-Day Market Update: Essendant Drops After Q3 Results; Achieve Life Sciences Shares Climb", "Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Estimates", "Mid-Afternoon Market Update: Buffalo Wild Wings Rises On Upbeat Earnings; Atossa Genetics Shares Plummet", "Anika (ANIK) Grows in Orthopedic Medicines on Positive Data", "The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics", "4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings", "New Strong Sell Stocks for July 11th", "Anika Therapeutics Receives FDA Nod for Bone Repair Therapy", "Health Care Sector Update for 05/22/2017: ANIK", "6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017", "Implied Volatility Surging for Anika Therapeutics (ANIK) Stock Options", "AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales", "AMAG Down Despite Positive Data on Makena Auto-Injector", "Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y", "BioMarin's Hemophilia Candidate Included in PRIME Initiative", "3 Naked Puts to Bank $1,000-Plus in July Cash", "Catabasis Hits 52-Week Low on Poor DMD Drug Study Data", "AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada", "Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues", "Allergan (AGN) Avycaz Label to Include New Phase III Data", "Exelixis Inks Partnership with Takeda for Cabometyx in Japan", "Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval", "Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid", "Novartis (NVS) Votubia Gets EU Approval for Label Expansion", "Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)", "Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study", "Endo (ENDP) Restructures its Branded Pharmaceutical Unit", "J&J to Acquire Actelion for $30B: Is It a Strategic Fit?", "AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA", "Immunogen Doses First Patient in Ovarian Cancer Drug Study", "AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag", "Novo Nordisk Inks Diabetes Deal with University of Oxford", "Celgene (CELG) Misses on Earnings & Revenues, Keeps View", "Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales", "AbbVie's HCV Regimen Okayed for Accelerated Assessment", "Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug", "Endo (ENDP) Settles Disputes with Federal Trade Commission", "Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission", "Marinus Releases Positive Preliminary Data from CDKL5 Study", "Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up", "Minerva Presents Additional Data from Schizophrenia Drug", "Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.", "Bristol-Myers Settles Litigation with Merck for Keytruda", "Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy", "Aduro (ADRO) Inks License Agreement with Stanford University", "Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA", "Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico", "HealthInvest Partners AB Buys Gilead Sciences Inc, McKesson Corp, Syneron Medical Ltd, Sells ...", "Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study", "Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter", "Concert Offers Update on Cystic Fibrosis Drug, Stock Down", "Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval", "Jazz Begins Phase III Study for Label Expansion of Defitelio", "AstraZeneca Offers Update on Immuno-Oncology Program", "Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo", "Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval", "Benitec Stock Up on Orphan Drug Status for BB-301 in EU", "Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit", "Allergan's Uterine Fibroids Candidate Positive in Phase III", "What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?", "Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017", "Steven Romick Spots Next Area of Investment Interest: Health Care", "Pluristem (PSTI) Intermittent Claudication Study Enrolled", "Kura Oncology Starts Dosing Patients in Phase II CMML Study", "Benitec Stock Up on Orphan Drug Status for BB-301 in EU", "AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder", "AbbVie's HCV Combo Favorable in Japanese Phase III Study", "Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments", "Vertex Pharma Issues Disappointing 2017 Orkambi Outlook", "Genocea Stock Up on Positive Genital Herpes Infections Data", "Biogen Licenses Amunix's XTEN Technology for Factor IX Drug", "Novartis to Conduct Trial on Obese, Type II Diabetes Patients", "Ultragenyx's (RARE) KRN23 Accepted for Review in the EU", "Argos Therapeutics (ARGS) Looks Good: Stock Rises by 5%", "Arena, Eisai Modify Marketing & Supply Agreement for Belviq", "Spark Therapeutics Gets $15M Milestone Payment from Pfizer", "Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained", "Clovis Declares Pricing of Upsized Offering of Common Stock", "Alexion (ALXN): Will the Stock Continue to Suffer in 2017?", "Halozyme (HALO) Up on Positive Phase II Data on PEGPH20", "Ultragenyx's (RARE) KRN23 Accepted for Review in the EU", "Neothetics (NEOT) Begins Phase II Study on Lead Candidate", "Horizon's Rare Disease Drug Quinsair Launched in Canada", "Celgene's Otezla Gains Positive Recommendation from NICE", "ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint", "3 Reasons Why Anika Therapeutics (ANIK) is a Great Momentum Stock", "Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?", "How Anika Therapeutics (ANIK) Stock Stands Out in a Strong Industry", "Pfizer Leukemia Drug Meets Primary Endpoint in Phase III", "Roche Presents Positive Follicular Lymphoma Data on Gazvya", "3 Biotech Stocks to Buy in December", "Aimmune Closes Enrolment in Phase III Peanut Allergy Study", "PhaseRx Soars on Orphan Drug Status for Rare Liver Disease", "Foamix Completes Enrolment in Phase III Acne Drug Studies", "AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US", "Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial", "Zacks.com featured highlights: Chemours, Matador Resources, Best Buy, Anika Therapeutics and McDermott International", "Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health", "OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.", "Merck (MRK) Announces 2.2% Increase in Quarterly Dividend", "Glaxo Nucala Favorable in Rare Vasculitis Disease Study", "Juno's ROCKET Study on Clinical Hold Again, Shares Down", "Cytori Scleroderma Study Two-Year Follow-Up Data Published", "Bristol-Myers' Opdivo Gets EU Approval for Label Expansion", "AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials", "Forget Earnings Growth, Focus on Beat with These 5 Stocks", "Ligand's Partner Retrophin Provides New Data on Sparsentan", "Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults", "Allergan's Fibristal Approved in Canada for Label Expansion", "Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017", "Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod", "Endo Reports Positive Cellulite Treatment Data on Xiaflex", "Keryx (KERX) Stock Up on Positive Phase III Auryxia Data", "Regeneron/Sanofi's Praluent CV Outcomes Study to Continue", "Sanofi/Regeneron Present Sarilumab Data at ACR Meeting", "Shire Launches Cuvitru in U.S. for Primary Immunodeficiency", "Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta", "SurModics (SRDX) Beats Q4 Earnings & Revenues Estimates", "Novartis/Amgen Migraine Drug Positive in Phase III Study", "Endo Reports Positive Cellulite Treatment Data on Xiaflex", "Keryx (KERX) Stock Up on Positive Phase III Auryxia Data", "Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y", "Ionis (IONS) Offers Positive Interim Data on Lipid Candidate", "Pfizer Reports Phase III Psoriatic Arthritis Data on Xeljanz", "Novartis Offers Positive Data on Cardiovascular Drug Entresto", "Spectrum (SPPI) Reports Narrower-than-Expected Q3 Loss", "Gilead Reports Phase III Myelofibrosis Data on Momelotinib", "Repros (RPRX) Reports Positive Top-Line Data on Proellex", "Amgen Presents Osteoporosis Data; Parsabiv Approved in EU", "Masimo (MASI) Gets $4.95 Million Gates Foundation Grant", "PRA Health Sciences (PRAH) Announces Secondary Offering", "Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma", "Gilead (GILD) HBV Drug Vemlidy Gets Positive CHMP Opinion", "LeMaitre (LMAT) Hits a 52-Week High on Strategic Buyout", "Celldex Stock Up on Positive Data on New Cancer Candidate", "Lily's Jardiance Effective in Lowering Cardiovascular Death", "AbbVie's (ABBV) Humira Wins CHMP Backing for Expanded Use", "Sanofi (SNY) Diabetes Drug Toujeo Positive in PK/PD Study", "VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3", "Baxter's Sigma Spectrum Infusion System Gets KLAS Award", "LeMaitre Vascular Buys Restore Flow Allografts for $14M", "AstraZeneca (AZN) Beats on Q3 Earnings; Sales Slow Down", "Bristol-Myers Offers Updates from Opdivo Combination Trials", "Intrexon (XON) Reports In-Line Loss in Q3, Revenues Miss", "VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3", "Kite Pharma Q3 Loss Betters Estimate; KTE-C19 On Track", "DexCom (DXCM) Incurs Wider Loss in Q3, Beats on Revenue", "Perrigo (PRGO) Beats on Q3 Earnings, Revenues; View Intact", "Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply", "Endocyte (ECYT) Stock Up on Lower-than-Expected Q3 Loss", "Infinity (INFI) Reports Narrower-than-Expected Loss in Q3", "Intrexon (XON) Reports In-Line Loss in Q3, Revenues Miss", "Mylan (MYL) Q3 Earnings & Revenues Miss on EpiPen Woes", "Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus", "BioDelivery (BDSI) Reports Wider-than-Expected Loss in Q3", "Impax (IPXL) Down on Q3 Earnings & Sales Miss, Cuts View", "Inovio (INO) Q3 Loss Wider than Expected, Revenues Beat", "TrovaGene (TROV) Reports Wider-than-Expected Loss in Q3", "Zacks.com featured highlights: McDermott International, NVIDIA, Nxstage Medical, Melco Crown Entertainment and Anika Therapeutics", "Jazz Pharma (JAZZ) Q3 Earnings Top, Sales Lag Estimates", "How Anika Therapeutics (ANIK) Stock Stands Out in a Strong Industry", "Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3", "Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall", "Valeant Pharma (VRX) Q3 Earnings Miss, Slashes Guidance", "Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus", "Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi", "Kite Pharma (KITE) Looks Good: Stock Adds 7% in Session", "Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise", "Emergent (EBS) Beats Earnings & Revenue Estimates in Q3", "On the Lookout for Earnings Beat? 5 Top Picks", "Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss", "Should You Get Rid of Capital Senior Living (CSU) Now?", "Aimmune Therapeutics (AIMT) Catches Eye: Stock Jumps 8.9%", "Endo (ENDP) Q3 Earnings & Revenues Beat; View Intact", "PDL BioPharma (PDLI) Q3 Earnings Lag, Revenues Fall Y/Y", "AMAG Pharma (AMAG) Q3 Earnings Up Y/Y, Revenues Beat", "What Makes Innoviva (INVA) a Strong Sell?", "Ironwood (IRWD) Posts Narrower-than-Expected Loss in Q3", "Radius Health (RDUS) Q3 Loss Match Estimates, Wider Y/Y", "Pacira (PCRX) Misses Q3 Earnings Estimates, Beats on Sales", "AmerisourceBergen (ABC) Q4 Earnings Top, Revenues Lag", "Achillion (ACHN) Reports Narrower-Than-Expected Q3 Loss", "Integra (IART) Catches Eye: Stock Adds 6% in Session", "Teva to Divest Actavis Generics' UK & Ireland Operations", "Alnylam (ALNY) Discontinues Phase III Study on Revusiran", "Cara Therapeutics (CARA) Catches Eye: Stock Moves Up 12%", "Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit", "Roche (RHHBY) Actemra Gets Breakthrough Therapy Status", "Bayer (BAYRY) Closes Registration Process for Kyleena in EU", "Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance", "Ocular Begins Enrollment in Phase III Trial on Glaucoma Drug", "Zacks.com featured highlights: Anika Therapeutics, Advanced Micro Devices, Edwards Lifesciences, Exact and Legacy Texas Financial Group", "The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals", "Editas Medicine (EDIT) Catches Eye: Stock Moves Up 11%", "Amgen Announces Publication of Blincyto Phase I/II Data", "Jazz Initiates Rolling NDA for Leukemia Candidate Vyxeos", "Alkermes Commences Metabolic Study on Schizophrenia Drug", "Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study", "Get Ready To Be Surprised This Earnings Season", "Emergent (EBS) Stock Up on Multi-Year NuThrax Vaccine Deal", "Regeneron's Eylea/Rinucumab Combination Data Disappoints", "AbbVie: HCV Regimen Obtains Breakthrough Therapy Status", "Horizon Pharma, Express Scripts to Settle Rebate Litigation", "ImmunoGen to Cut Workforce by 17% for Long Term Growth", "Endo International Reports Positive Phase II Data on Xiaflex", "Teva Boosts Generic Business with Allergan Anda Takeover", "Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug", "Jazz Pharma Closes Enrollment in OSA Drug Phase III Trial", "AcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso", "Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III", "Myriad Genetics to Present myRisk Data at Seattle Conference", "Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo", "Summit (SMMT): Rare Pediatric Disease Status for DMD Drug", "Intra-Cellular Reports Poor Phase III Schizophrenia Data", "Ionis/Biogen Complete Nusinersen NDA Submission in U.S.", "Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S.", "Novartis Ilaris Approved for Extended Use in Periodic Fever", "Achillion, J&J HCV Triple Combination Drug Data Presented", "Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.", "AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb", "Ligand Inks CNS License Agreement with Seelos Therapeutics", "AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica", "The Medicines Co. to Get BARDA Funding for Infection Drugs", "Gilead to Stop GS-5745 Development for Ulcerative Colitis", "Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up", "Amgen (AMGN) Repatha Meets Endpoints in Phase III Study", "Regeneron, Teva Collaborate to Develop Chronic Pain Drug", "BioDelivery Bunavail Gets Better Managed Care Positioning", "Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug", "Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study", "Celgene Presents Efficacy & Safety Phase II Ozanimod Data", "Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study", "Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology", "Qiagen: Molecular Diagnostics & Expansion Plans on Track", "Novavax Tanks, RSV F Vaccine Disappoints in Two Studies", "Teva/Intel Tie up for Huntington's Disease Technology Platform", "Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine", "Bayer (BAYRY) Strives for Increased Sales & Earnings Growth", "Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan", "Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel", "Ligand (LGND) Commences Phase II Type II Diabetes Study", "Will Bayer (BAYRY) Raise its Monsanto Buyout Offer Again?", "Repros Seeks EU Approval for Secondary Hypogonadism Drug", "Celgene's Crohn's Disease Drug Positive in Phase Ib Study", "J&J Files for Single-Tablet Regimen of HIV Drug Prezista in EU", "Bayer to Boost Agriculture Suite with $66B Monsanto Buyout", "Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan", "Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel", "Ligand (LGND) Commences Phase II Type II Diabetes Study", "Will Bayer (BAYRY) Raise its Monsanto Buyout Offer Again?", "Repros Seeks EU Approval for Secondary Hypogonadism Drug", "Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1", "Repros Therapeutics' (RPRX) Proellex Positive in Phase II", "Horizon (HZNP) to Acquire Raptor for $800M, Stock Soars", "Bristol-Myers' Orencia Gains EU Approval for Expanded Use", "BioMarin's (BMRN) Brineura Review Period Extended by FDA", "CoLucid Hits 52 Week High on Positive Data on Migraine Drug", "Glaxo Bexsero Meningitis B Immunization Shows Positive Data", "Masimo Amends Nellcor's Pulse Oximetry Royalty Agreement", "Bayer (BAYRY) Raises Offer to Purchase Monsanto Yet Again", "Astrazeneca (AZN) Presents Benralizumab Phase III Data", "Ligand/Retrophin Rare Disease Drug Positive in Phase II", "Bristol-Myers' Orencia Gains EU Approval for Expanded Use", "Merck Stops Development of Odanacatib for Osteoporosis", "Arena (ARNA) Beacon Discovery to Boost Research Platform", "Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.", "Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics", "Amgen Gets FDA Approval for Label Expansion of Blincyto", "Allergan, Adamas Agree to Settle Namzaric Patent Litigation", "Myriad Genetics Adds Assurex Health, Grows in Neuroscience", "Get Nice Earnings Surprise With These 5 Stocks", "Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data", "CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up", "Alexion's GVHD Candidate Gets Orphan Drug Status in the EU", "Amgen (AMGN) Reports Positive Data on Prolia and Repatha", "Macrocure Stock Up on Merger Deal with Leap Therapeutics", "Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away?", "Amarin (AMRN) Ends Patient Randomization in Vascepa Study", "Illumina Keen on Genome Network Growth & Global Expansion", "Amgen Gets CRL for Secondary Hyperparathyroidism Drug", "Gilead (GILD) Truvada Gets EU Approval for Label Expansion", "Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.", "Portola IndexXa's Regulatory Application Validated in the EU", "Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma", "Aclaris (ACRS) Common Warts Candidate Positive in Phase II", "Vanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20%", "Illumina Keen on Genome Network Growth & Global Expansion", "Why You Shouldn't Bet Against Anika Therapeutics (ANIK) Stock", "Actelion (ALIOF) Uptravi Approved for PAH in Switzerland", "Inovio (INO) Veterinary Vaccine Rights Licensed to Plumbline", "Radius (RDUS) Osteoporosis Drug Positive in Phase III Study", "Align Technology's Invisalign Dependence: Boon or Curse?", "FDA OKs Edwards Lifesciences' Sapien 3 for Extended Use", "Repros Presents 6-Month Interim Data on Enclomiphene", "UCB Epilepsy Drug Vimpat's Patent Validated by U.S. Court", "Vertex (VRTX) To Stop VX-661-Ivacaftor Study, Stock Down", "Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin", "CorMedix (CRMD) Shows Strength: Stock Moves Up 24.8%", "Allergan (AGN) Tops Q2 Earnings, Revises '16 Outlook", "Novo Nordisk (NVO) Beats Q2 Earnings, Revenues Up Y/Y", "FDA Approves Edwards Lifesciences' Intuity Elite Heart Valve", "Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus", "AVEO (AVEO) Reports a Wider Loss in Q2, Tivozanib in Focus", "Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q2", "Radius Health (RDUS) Reports Wider-than-Expected Q2 Loss", "Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales", "Array BioPharma (ARRY) in Focus: Stock Moves 9.3% Higher", "ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 6.9%", "BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped", "Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View", "ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q4", "Conatus (CNAT) Posts Narrower Q2 Loss, Emricasan in Focus", "Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus", "Zoetis (ZTS) Beats on Q2 Earnings & Revenues, Lifts Outlook", "Nivalis (NVLS) Reports Wider-than-Expected Loss in Q2", "Integra (IART) Tops Q2 Earnings, Grows Organically, Ups View", "Teva (TEVA) Beats on Q2 Earnings & Revenues, Stock Gains", "10 Biotech Stocks With Symptoms of Strong Growth", "Don't Try To Beat The Market's Traffic Jams", "Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View", "Baxalta (BXLT) Beats on Q1 Earnings, Set to Merge with Shire", "Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View", "Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook", "Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher", "Top Medical Companies Reach High Financial Strength", "Health Care Sector Update for 04/28/2016: ADXS,ANIK,NVDQ", "Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View", "Integra (IART) Beats on Q1 Earnings, Grows Organically", "GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y", "Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View", "New Strong Buy Stocks for April 27th", "Anika's Arthritis Treatment Gains Acceptance Among MDs, And Traders", "Top 5 Stocks with Increasing Cash Flows", "Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss", "Amgen's (AMGN) Phase III Study Results on Nplate Published", "Cytori Therapeutics (CYTX) Shows Strength: Stock Up 13.2%", "ARIAD Gains on Updated Brigatinib Phase I/II Study Data", "Gilead Presents Multiple HCV and HBV Data at Liver Congress", "Edge Therapeutics (EDGE) in Focus: Stock Rises 6.7%", "Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher", "Horizon Pharma Plunges on Bleak Q1 and 1H16 Guidance", "Clovis Drops, FDA Panel Seeks More Data on Rociletinib", "Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study", "GW Pharmaceuticals Begins Another Phase III Epidiolex Trial", "aTyr Pharma (LIFE) Jumps: Stock Adds 13.1% in Session", "TrovaGene Inks Strategic Partnership with Stratose, Stock Up", "AstraZeneca/Eli Lilly Alzheimer's Disease Drug in Phase III", "Repros Reveals Positive Data on Proellex for Uterine Fibroids", "Clovis Hits 52-week Low Post Rociletinib Briefing Documents", "Illumina Unveils BaseSpace Suite, Boosts Precision Medicine", "Why Sarepta Therapeutics Surged 20% in Wednesday Trading?", "Clovis Oncology (CLVS) Catches Eye: Stock Moves 6% Higher", "CytRx Corp (CYTR) in Focus: Stock Rises 10.2% in Session", "Glaxo's (GSK) Strimvelis Gets CHMP Nod for Rare Disorder", "Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use", "Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher", "Clovis Hits 52-week Low Post Rociletinib Briefing Documents", "Illumina Unveils BaseSpace Suite, Boosts Precision Medicine", "Alexion Pharmaceuticals' Kanuma Gains Approval in Japan", "Alder (ALDR) Surges on Positive Data on Migraine Candidate", "Pfizer's Revised Filing for Xeljanz Accepted for Review in EU", "Why You Shouldn't Bet Against Anika Therapeutics (ANIK) Stock?", "BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 8.1%", "Jazz's Hepatic VOD Drug Defitelio Gains FDA Nod, Shares Up", "Bio-Techne Buys Zephyrus, Boosts Protein Platforms Division", "Cara Therapeutics (CARA) Jumps: Stock Moves Up 21.3%", "Keryx Biopharmaceuticals (KERX) Jumps: Stock Rises 10.1%", "Eagle Pharmaceuticals Down on CRL for Kangio from FDA", "Celgene & Pfizer Present Data from Ulcerative Colitis Trials", "AstraZeneca's Heart Drug Brilinta Disappoints in Stroke Study", "MannKind (MNKD) Jumps: Stock Adds 17.5% in Session", "AMAG Initiates Enrolment in Phase III Study on Feraheme", "AVEO Q4 Loss Narrower than Expected, Tivozanib in Focus", "Axsome Therapeutics (AXSM) Jumps: Stock Rises 5.7%", "Eli Lilly Down, Alters Primary Endpoint of Solanezumab", "Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up", "Inovio (INO) 4Q Loss Wider than Expected, Pipeline in Focus", "What is Driving Shares of Endo (ENDP) Sharply Lower?", "MannKind (MNKD) Jumps: Stock Adds 17.5% in Session", "Should You Get Rid of Momenta Pharmaceuticals (MNTA) Now?", "Flex Pharma (FLKS) Jumps: Stock Adds 16.7% in Session", "Gilead's Zydelig under EU Review amid Safety Concerns", "Pfizer's Lung Cancer Drug Xalkori Label Expanded in U.S.", "BioDelivery (BDSI) Misses on Earnings and Revenue in Q4", "Sarepta Up, DMD Drug Eteplirsen to Face FDA Panel in April", "Prima Biomed (PBMD) Jumps: Stock Adds 25.6% in Session", "Spectrum (SPPI) Incurs Narrower-than-Expected Loss in Q4", "Conatus' Loss Narrower than Expected, Focus on Emricasan", "5 Stocks to Gain from Medical Device Excise Tax Exemption", "Sanofi, Merck to Dissolve Joint Vaccines Venture in Europe", "Celldex Advised to Discontinue Phase III Study on Rintega", "Catabasis Pharmaceuticals (CATB) Jumps: Stock Up 43.9%", "The Zacks Analyst Blog Highlights: CryoLife, Orthofix International, Anika Therapeutics, Computer Programs & Systems and Invitae", "Prima Biomed (PBMD) Jumps: Stock Adds 25.6% in Session", "Spectrum (SPPI) Incurs Narrower-than-Expected Loss in Q4", "Conatus' Loss Narrower than Expected, Focus on Emricasan", "5 Stocks to Gain from Medical Device Excise Tax Exemption", "Baxalta Seeks EU Approval for Hemophilia A Drug Adynovi", "Nektar (NKTR) Reports Narrower-than-Expected Q4 Loss", "Qiagen: Molecular Diagnostics a Drag, Currency Woes Persist", "Amgen Seeks FDA Approval for Blincyto's Label Expansion", "Horizon (HZNP) Misses on Q4 Earnings, Beats on Revenues", "Intrexon (XON) Reports Wider Q4 Loss, Beats on Revenues", "Puma (PBYI) Reports In Line Q4 Loss, Neratinib in Focus", "Asterias Biotherapeutics (AST) Jumps: Stock Moves Up 17.9%", "Fate Therapeutics (FATE) Catches Eye: Stock Rises 8.3%", "Safer Small-Cap Investing Puts Focus On Quality", "Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 12.6%", "Amgen Seeks FDA Approval for Blincyto's Label Expansion", "Horizon (HZNP) Misses on Q4 Earnings, Beats on Revenues", "Endo (ENDP) Tops Q4 Earnings Estimates, Gives 2016 Outlook", "Bayer (BAYRY) Q4 Earnings Lag Estimates, Gives 2016 View", "Sarepta's Q4 Loss Wider than Expected, Eteplirsen in Focus", "Keryx Posts Wider-than-Expected Loss in Q4, Auryxia Grows", "Athersys (ATHX) Worth a Look: Stock Adds 7.1% in Session", "Valeant's (VRX) CEO Pearson Returns, 2015 Results Delayed", "BioMarin Incurs Loss in Q4, Misses Estimates, Gives '16 View", "Radius Health (RDUS) Posts Wider-than-Expected Loss in Q4", "Aegerion Q4 Loss Narrower than Expected, Pipeline in Focus", "Alkermes Q4 Loss Narrower than Expected, Updates Pipeline", "Retrophin's RE-024 Granted Orphan Drug Status in EU", "Jazz Tops Q4 Earnings, Revenues Up Y/Y, Gives 2016 View", "Infinity (INFI) Q4 Loss Narrower than Expected, Revenues Lag", "Anika Therapeutics (ANIK) Jumps: Stock Moves Up 8%", "Valeant Issues Restatement of Financial Results, Shares Down", "Impax Q4 Earnings Surpasses Expectations, Revenues Beat", "Allergan (AGN) Beats on Q4 Earnings, Revenues Soar Y/Y", "AstraZeneca Zurampic Gets EU Nod, Brilique Label Expanded", "Prothena Q4 Loss Narrower than Expected, Pipeline in Focus", "Agios' (AGIO) Q4 Loss Wider than Expected, Pipeline in Focus", "Zafgen Up, Beloranib Hits Phase IIb Primary Efficacy Endpoint", "ARIAD Incurs Wider-than-Expected Loss in Q4, Shares Down", "Valeant Issues Restatement of Financial Results, Shares Down", "Impax Q4 Earnings Surpasses Expectations, Revenues Beat", "AstraZeneca Cancer Drug Gets Breakthrough Therapy Status", "Catalyst (CPRX) Down on FDA's Refusal to File Firdapse NDA", "AMAG Q4 Earnings & Revenues Up Y/Y, Gives 2016 Outlook", "Argos Therapeutics (ARGS) Jumps: Stock Rises 16.2%", "Gilead's HCV Drug Harvoni Approved in Two More Indications", "Perrigo Lags on Q4 Earnings and Revenues, Updates View", "Repros Updates on Proof-of-Concept Study on Enclomiphene", "Baxalta (BXLT) Beats on Q4 Earnings, Set to Merge with Shire", "Intercept Pharmaceuticals (ICPT) Soars on Buyout Rumors", "Merck (MRK) Gets CRL for Zetia & Vytorin sNDA from FDA", "Amgen's Aranesp Meets Primary Endpoint in Phase III Study", "Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus", "Clovis' (CLVS) Rociletinib to Face FDA Advisory Panel in April", "Flexion's (FLXN) Pain Drug Zilretta Tops Phase III Study", "Repros Updates on Proof-of-Concept Study on Enclomiphene", "Baxalta (BXLT) Beats on Q4 Earnings, Set to Merge with Shire", "Intercept Pharmaceuticals (ICPT) Soars on Buyout Rumors", "Merck (MRK) Gets CRL for Zetia & Vytorin sNDA from FDA", "Amgen's Aranesp Meets Primary Endpoint in Phase III Study", "Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus", "Mylan Q4 Earnings and Revenues Lag, Set To Acquire Meda", "Eli Lilly's Alimta Gets Negative Ruling in UK Patent Lawsuit", "Heat Biologics Up as FDA Lifts Partial Hold on Phase II Study", "Sanofi Tops Q4 Earnings, Revenues Fall Y/Y, Gives 2016 View", "INSYS (INSY) Initiates Phase II Study for Infantile Spasms", "Seattle Genetics' (SGEN) Q4 Loss Wider than Expected", "Cambrex (CBM) Shows Strength: Stock Moves 5.1% Higher", "Cytori Tanks on Unfavorable Data from Osteoarthritis Study", "Epizyme's Tazemetostat Gets Orphan Drug Status in the U.S.", "Kura Oncology (KURA) Rises: Stock Adds 6.8% in Session", "Immunomedics (IMMU) in Focus: Stock Moves 20.9% Higher", "Amgen's Blincyto and Repatha Positive in Phase III Studies", "Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies", "AstraZeneca Tops Q4 Earnings, Falls on Bleak 2016 Outlook", "Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact", "Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3%", "Repros, FDA Meet to Discuss Issues of Enclomiphene's CRL", "Sarepta Hits 52-Week Low; Eteplirsen Review Period Extended", "Immunomedics (IMMU) in Focus: Stock Moves 20.9% Higher", "Amgen's Blincyto and Repatha Positive in Phase III Studies", "Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies", "Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over", "Argos Therapeutics (ARGS) Jumps: Stock Moves Up 19.6%", "Jazz's Phase III Data on Defibrotide Published in ASH Journal", "Qiagen Q4 Earnings Miss, Molecular Diagnostics Disappoints", "Prothena (PRTA) Looks Good: Stock Jumps 5.1% in Session", "Spectrum (SPPI) Initiates Phase III Study on SPI-2012", "SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates", "Inovio Pharmaceuticals (INO) Jumps: Stock Moves Up 7.6%", "AstraZeneca's Lynparza Gets Breakthrough Therapy Status", "Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price", "Exelixis's Cabozantinib Granted Priority Review in the U.S.", "ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16", "Clovis (CLVS) Begins Immunotherapy Combination Study", "Argos Therapeutics (ARGS) Catches Eye: Stock Rises 35.9%", "Alkermes Initiates Early-Stage Study on Alzheimer's Drug", "Affimed & Merck Ink Deal for AFM13-Keytruda Combination", "Amgen's Biosimilar of AbbVie's Humira under FDA Review", "OncoMed Tanks on Phase II Pancreatic Cancer Study Update", "Fate (FATE) to Move ProTmune into Phase I/II Study in Mid-16", "MannKind (MNKD) Shows Strength: Stock Moves 14% Higher", "Agenus (AGEN) Catches Eye: Stock Adds 8.8% in Session", "Amgen Kyprolis' Label Expanded, Repatha Approved in Japan", "MannKind (MNKD) Signs Deal with Receptor Life Sciences", "Alkermes Hit 52-Week Low on Unfavorable Phase III Data", "Halozyme Therapeutics (HALO) in Focus: Stock Rises 6.7%", "Zafgen Soars on Positive Phase III Efficacy Data on Beloranib", "Cymabay Gives Update on Phase III Program on Arhalofenate", "Amgen Presents Encouraging Phase III Data on Vectibix", "Biotie Therapies Soars on $363M Buyout Deal with Acorda", "Synthetic Biologics Posts Encouraging Data on SYN-010", "Eleven Biotherapeutics' Eye Drug Fails in Phase III Study", "Heron (HRTX) Down, Sustol Review Period Extended by FDA", "Impax's Emverm Approved for Parasitic Worm Infestations", "Nivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis", "Sarepta Tanks, Eteplirsen Briefing Document Raises Concerns", "J&J Plans to Cut 3,000 Medical Devices Jobs, 2015 View Intact", "Ultragenyx Pharmaceutical (RARE) in Focus: Stock Tumbles 11.2%", "How Anika Therapeutics (ANIK) Stock Stands Out in a Strong Industry", "Incyte Corporation (INCY) in Focus: Stock Plunges 11%", "Ligand, Emergent BioSolutions Tie Up for OmniAb Technology", "Pluristem (PSTI) Gets FDA Approval for Phase I PLX-R18 Trial", "Kite Pharma Signs Deal with Leiden University Medical Center", "Horizon (HZNP) Ups View on Crealta Holdings Deal, Shares Up", "Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins", "Alnylam Provides Update on RNAi Therapeutics Pipeline", "Qiagen Q4 and 2015 Preliminary Results Dim; Shares Tank 13%", "Celgene (CELG) Drops on Preliminary Results & 2016 Outlook", "Acorda's Ampyra Ends 2015 on Strong Note, Pipeline in Focus", "Weakness Seen in Chiasma (CHMA): Stock Slumps 16%", "Weakness Seen in bluebird (BLUE) : Stock PLunges 19.5%", "SurModics Buys NorMedix for $14M, Adjusts 2016 Outlook", "Zoetis 2016 and 2017 View Impacted by Tax Woes in Belgium", "Perrigo (PRGO) Raises 2016 Earnings Guidance, Shares Up", "Agios (AGIO) Provides Pipeline Updates and 2016 Strategy", "New Strong Buy Stocks for January 11th", "uniQure N.V. (QURE) Shows Strength: Stock Moves Up 5.3%", "ARIAD's Iclusig Regulatory Application Filed in Japan", "Sanofi Inks Multiple Deals, Sarilumab under FDA Review", "Vertex (VRTX) Gives 2016 View, Orkambi View to Come Later", "BioMarin Reveals Interim Data from Pompe Disease Study", "AbbVie Starts Phase III Program on ABT-494 for RA Treatment", "Baxalta Incorporated (BXLT) Jumps: Stock Moves Up 5.5%", "Cara Therapeutics (CARA) Jumps: Stock Moves Up 6.8%", "Sarepta's DMD Drug Eteplirsen to Face FDA Panel in January", "Anika (ANIK) Starts Enrolment in Phase III HyaloFast Study", "Epizyme's Tazemetostat IND Application Accepted for DLBCL", "Sanofi's Dengue Vaccine Dengvaxia Gains Brazilian Approval", "Integra Strong on International Growth; US Spine Bothers", "Eagle's (EGRX) Non-Alcoholic Docetaxel Gets FDA Approval", "Takeda, Teva Reveal Outlook of Japanese Business Venture", "Sanofi Seeks FDA Approval for Diabetes Drug Combination", "Agenus Acquires PhosImmune, Adds Cancer Neoantigens", "Argos Therapeutics (ARGS) Catches Eye: Stock Rises 6.4%", "Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds", "Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab", "Evogene (EVGN) Shows Strength: Stock Moves Up 9%", "Celyad's C-Cure IND Authorized in U.S. for Phase III Study", "Actelion's Uptravi Approved in the U.S. for PAH Treatment", "Should You Dump Cardiovascular Systems (CSII) Now?", "Baxalta's Adynovate Positive in Phase III Pediatric Study", "Repros Provides Update on Proellex Program, Data by 3Q16", "Alnylam Submits Clinical Trial Application for ALN-GO1 in UK", "Aduro Doses First Patient in Phase I Study on ADU-741", "AstraZeneca's Zurampic FDA Approved with Boxed Warning", "Atara Biotherapeutics (ATRA) Jumps: Stock Moves Up 6%", "AstraZeneca Updates on Durvalumab; CHMP Favors 3 Drugs", "aTyr Pharma (LIFE) Jumps: Stock Moves 18.8% Higher", "Intercept (ICPT) Down on Delay in FDA's Verdict on Lead Drug", "Alnylam Initiates Final Part of Phase I/II Study on ALN-CC5", "Array BioPharma (ARRY) Jumps: Stock Moves Up 20.6%", "Alkermes Hits 52 Week High on Pipeline Update & Aristada", "Myriad Genetics: Test Expansion Strong, Currency Woes Linger", "Atara Biotherapeutics (ATRA) Jumps: Stock Moves Up 6%", "AstraZeneca Updates on Durvalumab; CHMP Favors 3 Drugs", "Atara Plunges on Poor Results from Phase II PINTA 745 Study", "Horizon (HZNP) To Acquire Crealta Holdings in a $510M Deal", "Otonomy's Ear Infection Drug Otiprio Approved in the U.S.", "ARIAD Lowers Iclusig's 2015 Revenue Outlook, Shares Fall", "Evotec/Spero Deal Extended For Gram-negative Bacteria", "Raptor Reports Efficacy Data from CYST-HD Study on RP103", "Sanofi's Dengue Vaccine Dengvaxia Gets Mexican Approval", "OncoGenex to Continue with Borealis-2 Study on Apatorsen", "Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab", "Gilead Reveals Encouraging Data on Leukemia Drug Zydelig", "ProQR Therapeutics (PRQR) Rises: Stock Up 6.1% in Session", "Cara Therapeutics (CARA) Jumps: Stock Moves Up 10.2%", "Caladrius Biosciences (CLBS) Jumps: Stock Moves Up 6.5%", "Alexion (ALXN) Gains after Kanuma Receives FDA Approval", "Should You Retain Integra LifeSciences (IART) in Your Portfolio?", "GW Pharmaceuticals Posts Narrower-than-Expected Q4 Loss", "Stemline Therapeutics (STML) Jumps: Stock Moves Up 5.6%", "Kite Pharma Begins Study on KTE-C19, Presents Data at ASH", "Celgene/AstraZeneca Start Immuno-Oncology Drug Studies", "Bluebird Bio Crashes After Clinical Trial Update", "Baxalta's Vonvendi Gets FDA Nod for Von Willebrand Disease", "Alexion (ALXN) Gains after Kanuma Receives FDA Approval", "Should You Retain Integra LifeSciences (IART) in Your Portfolio?", "Cytori Reports Positive Top-Line Data on ECCS-50 Yet Again", "Baxalta Wins CHMP Backing for Sanquin to Start Production", "Anika (ANIK): Moving Average Crossover Alert", "Synthetic (SYN) Unveils Positive Phase IIb Data on SYN-004", "Repros Hits 52-Week Low after Enclomiphene Receives CRL", "Should You Dump Illumina (ILMN) from Your Portfolio Now?", "Puma (PBYI) Updates on Neratinib's Progress in Europe", "Horizon's (HZNP) Ravicti Ok'd in EU for Urea Cycle Disorders", "Intercept (ICPT) Initiates Study on Another Bile Acid Analog", "Why Anika Therapeutics (ANIK) Stock Might be a Great Pick", "KaloBios Surges 30%, Martin Shkreli Stops Lending Shares", "Impax's Parkinson's Disease Drug Numient Approved in EU", "Ocular Begins Second Phase III Allergic Conjunctivitis Study", "Axovant Sciences (AXON) Jumps: Stock Moves Up 9.8%", "Eli Lilly's Portrazza Gets FDA Nod, Carries Boxed Warning", "BioMarin's Vimizim Gets NICE Recommendation in England", "Why Anika Therapeutics (ANIK) Could Be Positioned for a Surge?", "Synthetic Biologics (SYN) Rises: Stock Adds 11% in Session", "AMAG Responds to FDA's CRL for Single-Dose Vial of Makena", "BioMarin Down on FDA's Briefing Document on Kyndrisa", "AstraZeneca, Sanofi to Swap 210,000 Chemical Compounds", "Peregrine Pharmaceuticals (PPHM) Jumps: Stock Up 6.1%", "SurModics Buys Balloon Catheter Maker Creagh Medical", "Amgen's Multiple Myeloma Drug Kyprolis Gains EU Approval", "Aduro (ADRO) Creates Subsidiary, Aduro Biotech Europe", "Global Blood Therapeutics (GBT) Jumps: Stock Up 16.7%", "AMAG Receives Another CRL for Single-Dose Vial of Makena", "Spectrum (SPPI) Up on Selling Zevalin Rights to Mundipharma", "Protalix Meets FDA, To Start Phase III Fabry Disease Study", "Celldex Jumps on Phase II Overall Survival Data on Rintega", "Array (ARRY)/Pierre Fabre Collaborate for Cancer Drugs", "Looking for a Top Momentum Stock? 3 Reasons Why Anika Therapeutics (ANIK) is a Great Choice", "Repros Provides Update on Phase IIb Study on Proellex", "Illumina (ILMN) Set to Enter the Coveted S&P 500, Stock Up", "Genomic Health Overseas Business Strong, Margin Woes Stay", "Catalyst Pharmaceuticals' Q3 Loss Narrower than Expected", "Repros' Q3 Loss Narrower than Expected, Pipeline in Focus", "Clovis Crashes 70%, FDA Seeks More Data on Rociletinib", "BioDelivery (BDSI) Down on Wider-than-Expected Q3 Loss", "Intrexon (XON) Reports Wider-than-Expected Loss in Q3", "Puma Biotechnology Reports Wider-than-Expected Q3 Loss", "TrovaGene Rallies despite Wider-than-Expected Q3 Loss", "Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss", "Clovis Posts Wider-than-Expected Loss in Q3, Shares Down", "Horizon (HZNP) Up on Q3 Earnings Beat, Raises Guidance", "AVEO (AVEO) Swings into Earnings in Q3, Revenues Up Y/Y", "Emergent BioSolutions Tops Q3 Earnings and Revenues", "Nektar (NKTR) Reports Narrower-than-Expected Q3 Loss", "Synta Q3 Loss Narrower than Expected, to Cut Jobs by 60%", "Agios' (AGIO) Q3 Loss Wider than Expected, Pipeline in Focus", "Gilead's (GILD) Cocktail HIV Drug Genvoya Gets FDA Nod", "Conatus Posts Wider-than-Expected Loss, Emricasan in Focus", "Celgene Tops Q3 Earnings, Keeps 2015 Bottom-Line View", "Dr. Reddy's (RDY) Receives FDA Warning Letter; Shares Fall", "Myriad Genetics Tops Q1 Earnings, Revenues; Keeps '15 View", "Henry Schein Tops Q3 Earnings, Revenues; Tweaks '15 View", "Genomic Health Q3 Loss Wider than Expected, '15 View Kept", "Integra LifeSciences Tops Q3 Earnings, Revenues; View Up", "Portola's Phase III Study on Betrixaban Completes Enrollment", "QLT (QLTI) Reports Narrower-than-Expected Loss in Q3", "Bayer (BAYRY) Q3 Revenues Up Y/Y, 2015 View Adjusted", "Gilead's Sovaldi in Focus on Bradyarrhythmia Concerns", "Strength Seen in Anika Therapeutics (ANIK): Stock Up 7.1%", "Mylan Tops Q3 Earnings, Misses Revenues, Updates View", "Alexion Beats on Earnings in Q3 but Misses on Revenues", "Qiagen Misses on Q3 Earnings and Revenues, Liquidity Strong", "AMAG to Initiate Head-to-Head Phase III Study on Feraheme", "Gilead (GILD) Beats on Q3 Earnings, HCV Drugs Lose Shine", "Trimble Navigation's (TRMB) Q3 Earnings: What Lies Ahead?", "GNC Holdings Earnings, Revenues Lag; Franchise Unit Strong", "Alexion (ALXN) to Report Q3 Earnings: What to Expect?", "What Awaits BioMarin (BMRN) This Earnings Season?", "BioDelivery/Endo Up on FDA Approval of Pain Drug Belbuca", "TE Connectivity (TEL) Q4 Earnings Likely to Disappoint?", "GoPro (GPRO) Preview: Can It Pull an Earnings Surprise?", "Will Macroeconomic Woes Hurt FLIR Systems' Q3 Earnings?", "Can Alliance Fiber (AFOP) Earnings Pull a Surprise in Q3?", "Bristol-Myers Beats on Q3 Earnings, Guidance Encouraging", "Will Ingersoll (IR) Q3 Earnings Disappoint This Season?", "Waste Management (WM) Q3 Earnings: What to Expect?", "Will the Earnings Streak Continue for VASCO (VDSI) in Q3?", "Can Bristol-Myers (BMY) Sustain Earnings Momentum in Q3?", "What's in Store for Gilead (GILD) this Earnings Season?", "Can Broadcom (BRCM) Surprise on Q3 Earnings This Time?", "Synta Falls, Stops Ganetespib Late-Stage Lung Cancer Study", "Foamix Starts Patient Enrollment in Phase II Study on FMX103", "Illumina Tops Q3 Earnings, Meets Revenues; '15 View Cut", "Will Generic Segment Drive Perrigo (PRGO) Q3 Earnings Beat?", "What to Expect from Overstock.com's (OSTK) Q3 Earnings?", "Cypress Semiconductor (CY) Q3 Earnings: What's in Store?", "Texas Instruments (TXN) Q3 Earnings: What to Expect?", "BioMarin's Drisapersen to be Reviewed by FDA's Committee", "Zafgen Continues to Fall; Partial Clinical Hold on Beloranib", "eBay's (EBAY) 1st Earnings without PayPal: What's in Store? (revised)", "Will Hubbell (HUB-B) Disappoint Earnings Estimates in Q3?", "CMS Hikes Medicare Rate for Genomic's Breast Cancer Test (Revised)", "Will Nielsen's (NLSN) Earnings Disappoint Estimates in Q3?", "Medicare Initiates Coverage on Genomic Prostate Cancer Test", "What to Expect from Lam Research's (LRCX) Q1 Earnings?", "eBay's (EBAY) 1st Earnings without PayPal: What's in Store?", "Will Nielsen's (NLSN) Earnings Disappoint Estimates in Q3?", "What's in Store for Morningstar (MORN) in Q3 Earnings?", "Alnylam Offers Data on ALN-TTRsc02 & Platform Technology", "Zafgen Reports Patient Death in Late-Stage Beloranib Study", "Aimmune Therapeutics (AIMT) Jumps: Stock Rises 13.7%", "Incyte & Merck Expand Melanoma Treatment Collaboration", "Theravance (TBPH) Advances TD-0714, Submits IND to FDA", "Xenoport (XNPT) Shows Strength: Stock Moves Up 9.3%", "BioMarin Presents Data on Vosoritide at Medical Meeting", "Portola's Betrixaban Gets Fast Track Designation in the U.S.", "Alexion (ALXN) Presents Positive 5-Year Data on Strensiq", "CMS Hikes Medicare Rate for Genomic's Breast Cancer Test", "Dyax Corp. (DYAX) Catches Eye: Stock Adds 7.3% in Session", "Bristol-Myers Cancer Drug Opdivo's Label Expanded in U.S.", "Radius (RDUS) Reports Positive Data on Osteoporosis Drug", "Galapagos (GLPG) Reports Positive Data on GLPG1837", "Qiagen Poised on Molecular Diagnostics, International Business", "Celgene (CELG) Posts Encouraging One-Year Data on Otezla", "Alnylam Initiates Extension Study on ALN-AT3 for Hemophilia", "Verastem (VSTM) Shows Strength: Stock Moves Up 15.2%", "AcelRx Updates on Zalviso for Pain Management Treatment", "GTX (GTXI) Shows Strength: Stock Adds 37.8% in Session", "Infinity (INFI) Updates on Duvelisib and IPI-549 on R&D Day", "ANI Pharmaceuticals (ANIP) in Focus: Stock Surges 10.5%", "Acorda Therapeutics (ACOR) Jumps: Stock Moves Up 12%", "Aduro Gets Milestone Payment for ADU-214's IND Submission", "Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion", "OncoMed Pharmaceuticals (OMED) Rises: Stock Gains 13%", "Incyte (INCY) Shows Strength: Stock Adds 7.2% in Session", "Illumina Poised on Product Innovation, Global Expansion", "Bristol-Myers' Melanoma Combo Opdivo/Yervoy Gets FDA Nod", "Illumina Downgraded by Leerink, Shares Plummet Over 10%", "Integra (IART) Hopeful on Spine Spin-Off amid Global Woes", "Illumina (ILMN) Shares Tumble on Weak Outlook for Sales", "Cara Therapeutics (CARA) Jumps: Stock Moves Up 16.6%", "Infinity (INFI) Up, Set to Get Duvelisib Milestone Payment", "The Zacks Analyst Blog Highlights: Express Scripts, AbbVie, Amgen, Anika Therapeutics and PDL BioPharma", "Lexicon Presents Positive Data from Telotristat Etiprate Study", "Anika Therapeutics (ANIK) Is in Oversold Territory: What's Next?", "Weakness Seen in bluebird (BLUE): Stock Tumbles 13.3%", "Endo Completes $8.05B Par Pharma Acquisition, Updates View", "New Strong Buy Stocks for October 1st", "Health Care Sector Update for 08/28/2015: NVO, GHDX, ANIK", "Anika Stock: What is the Social Media Crowd Thinking About ANIK?", "Why Anika Therapeutics Gained 13% in July", "Commit To Buy Anika Therapeutics At $30, Earn 6.7% Annualized Using Options", "3 Biotech Stocks to Buy in December", "Commit To Purchase Anika Therapeutics At $35, Earn 10.3% Annualized Using Options", "Mid-Day Market Update: First Solar Falls On Downbeat Results; Anika Therapeutics Shares Jump", "Anika Therapeutics Stock: 3 Reasons Why ANIK Is a Top Choice for Value Investors", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "Supernus Files Patent Infringement Lawsuit - Analyst Blog", "MDCO Acquires ProFibrix - Analyst Blog", "Data on BioLineRx' BL-8040 - Analyst Blog", "Osiris Loss Wider-Than-Expected - Analyst Blog", "Wider-than-Expected Loss at Avanir - Analyst Blog", "Narrower-than-Expected Loss at Pacira - Analyst Blog", "Mid-Morning Market Update: Markets Edge Higher; Lowe's Q4 Profit Surges 6.3%", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "Loss Narrows at Dynavax in Q2 - Analyst Blog", "DaVita and Myriad Join Forces - Analyst Blog", "Data on Astex Candidate - Analyst Blog", "Good News for Celgene's Revlimid - Analyst Blog", "Amgen Xgeva Label Expanded - Analyst Blog", "Pacira's Exparel Disappoints - Analyst Blog", "CELG Presents Positive Long-term Data - Analyst Blog", "Xenon Licenses Isis Drug - Analyst Blog", "Dynavax Down on Heplisav Delay - Analyst Blog", "SGEN Starts Adcetris Phase I/II Study - Analyst Blog", "Encouraging Data on Alexion's Soliris - Analyst Blog", "Priority Review for Gilead Drug - Analyst Blog", "Encouraging Data on Isis Candidate - Analyst Blog", "Myriad: End to Legal Battle over Patents - Analyst Blog", "The Medicines Co. Inks Deal with ProFibrix - Analyst Blog", "FDA Issues Warning Letter to Novartis - Analyst Blog", "Setback for Pluristem Therapeutics - Analyst Blog", "Canada Nod for Medivation's Xtandi - Analyst Blog", "Roche Presents Data on Avastin - Analyst Blog", "CHMP Positive on Teva's Lonquex - Analyst Blog", "Biogen Delays EU Launch of Tecfidera - Analyst Blog", "Astellas, Tecnofarma in Distribution Deal - Analyst Blog", "Encouraging News for Peregrine Pharma - Analyst Blog", "New Diagnostic Solution from Roche - Analyst Blog", "Promising Data on ONCY's Reolysin - Analyst Blog", "Encouraging News for Peregrine Pharma - Analyst Blog", "Biogen Submits Plegridy BLA - Analyst Blog", "XenoPort Candidate Disappoints - Analyst Blog", "Biogen's Hemophilia BLA Accepted - Analyst Blog", "Medivation/Astellas Seek Xtandi Approval in Japan - Analyst Blog", "Pediatric Approval for MDCO/BMY's Recothrom - Analyst Blog", "Amgen to Set Up JV in China - Analyst Blog", "Disappointing 1Q Earnings for IART - Analyst Blog", "Wider-than-Expected Loss at Dynavax - Analyst Blog", "Zacks #1 Rank Additions for Thursday - Tale of the Tape", "WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE", "Zacks #5 Rank Additions for Monday - Tale of the Tape", "SGEN's Adcetris under FDA Review - Analyst Blog", "Zacks #5 Rank Additions for Friday - Tale of the Tape", "Zacks #5 Rank Additions for Wednesday - Tale of the Tape", "Zacks #5 Rank Additions for Thursday - Tale of the Tape", "Zacks #5 Rank Additions for Thursday - Tale of the Tape", "Zacks #5 Rank Additions for Tuesday - Tale of the Tape", "Zacks #5 Rank Additions for Wednesday - Tale of the Tape", "Zacks #5 Rank Additions for Friday - Tale of the Tape", "Zacks #5 Rank Additions for Wednesday - Tale of the Tape", "Zacks #5 Rank Additions for Monday - Tale of the Tape", "Stocks Down at Mid-Day, But Off Lows, as Investors Digest Mixed Economic Data", "Mid-Day Update: Stocks Down on Economic Data; Investors Eye NYSE, Deutsche Boerse Deal", "Zacks #5 Rank Additions for Wednesday - Tale of the Tape"], "Elapsed Time": ["MAY 8, 2020", "MAR 18, 2020", "FEB 21, 2020", "FEB 20, 2020", "FEB 16, 2020", "JAN 19, 2020", "DEC 15, 2019", "DEC 15, 2019", "MAY 8, 2020", "DEC 11, 2019", "OCT 24, 2019", "JUL 25, 2019", "JUL 25, 2019", "JUL 25, 2019", "MAY 2, 2019", "APR 23, 2019", "DEC 11, 2019", "FEB 21, 2019", "FEB 14, 2019", "DEC 24, 2018", "DEC 21, 2018", "DEC 17, 2018", "DEC 14, 2018", "DEC 10, 2018", "FEB 22, 2019", "OCT 24, 2018", "OCT 24, 2018", "OCT 22, 2018", "OCT 17, 2018", "SEP 28, 2018", "SEP 27, 2018", "SEP 26, 2018", "OCT 29, 2018", "SEP 25, 2018", "SEP 25, 2018", "SEP 25, 2018", "SEP 7, 2018", "SEP 5, 2018", "SEP 4, 2018", "AUG 31, 2018", "SEP 25, 2018", "JUN 21, 2018", "JUN 20, 2018", "JUN 20, 2018", "JUN 20, 2018", "JUN 20, 2018", "MAY 18, 2018", "MAY 3, 2018", "JUN 22, 2018", "APR 20, 2018", "APR 16, 2018", "APR 6, 2018", "APR 2, 2018", "MAR 16, 2018", "FEB 27, 2018", "FEB 23, 2018", "MAY 3, 2018", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "AUG 15, 2017", "JUL 18, 2017", "JUL 17, 2017", "JUL 11, 2017", "JAN 3, 2018", "MAY 22, 2017", "MAR 30, 2017", "MAR 14, 2017", "FEB 3, 2017", "FEB 3, 2017", "FEB 3, 2017", "FEB 2, 2017", "JUL 6, 2017", "FEB 2, 2017", "FEB 2, 2017", "JAN 31, 2017", "JAN 31, 2017", "JAN 31, 2017", "JAN 31, 2017", "JAN 30, 2017", "FEB 2, 2017", "JAN 30, 2017", "JAN 27, 2017", "JAN 27, 2017", "JAN 27, 2017", "JAN 27, 2017", "JAN 27, 2017", "JAN 27, 2017", "JAN 30, 2017", "JAN 26, 2017", "JAN 26, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 24, 2017", "JAN 24, 2017", "JAN 24, 2017", "JAN 26, 2017", "JAN 23, 2017", "JAN 23, 2017", "JAN 23, 2017", "JAN 20, 2017", "JAN 20, 2017", "JAN 20, 2017", "JAN 19, 2017", "JAN 24, 2017", "JAN 19, 2017", "JAN 19, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 19, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 13, 2017", "JAN 13, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 13, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 4, 2017", "JAN 4, 2017", "JAN 6, 2017", "JAN 6, 2017", "DEC 28, 2016", "DEC 27, 2016", "DEC 23, 2016", "DEC 21, 2016", "DEC 20, 2016", "JAN 3, 2017", "DEC 14, 2016", "DEC 6, 2016", "DEC 6, 2016", "DEC 1, 2016", "NOV 30, 2016", "NOV 30, 2016", "NOV 30, 2016", "DEC 20, 2016", "NOV 29, 2016", "NOV 25, 2016", "NOV 25, 2016", "NOV 25, 2016", "NOV 24, 2016", "NOV 24, 2016", "NOV 24, 2016", "NOV 30, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 21, 2016", "NOV 23, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 16, 2016", "NOV 16, 2016", "NOV 16, 2016", "NOV 16, 2016", "NOV 15, 2016", "NOV 17, 2016", "NOV 15, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 15, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 12, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 14, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 10, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 8, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 2, 2016", "NOV 7, 2016", "OCT 31, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 6, 2016", "OCT 5, 2016", "OCT 5, 2016", "NOV 2, 2016", "OCT 5, 2016", "OCT 5, 2016", "OCT 5, 2016", "OCT 5, 2016", "OCT 4, 2016", "OCT 4, 2016", "OCT 4, 2016", "OCT 5, 2016", "OCT 4, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 4, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 29, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 23, 2016", "SEP 27, 2016", "SEP 22, 2016", "SEP 22, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 23, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 19, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 15, 2016", "SEP 20, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 9, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 13, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 8, 2016", "SEP 5, 2016", "SEP 5, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 1, 2016", "SEP 6, 2016", "SEP 1, 2016", "AUG 31, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 29, 2016", "SEP 1, 2016", "AUG 26, 2016", "AUG 25, 2016", "AUG 23, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 19, 2016", "AUG 19, 2016", "AUG 26, 2016", "AUG 26, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 19, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 12, 2016", "AUG 8, 2016", "AUG 8, 2016", "AUG 17, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 2, 2016", "AUG 1, 2016", "AUG 5, 2016", "MAY 31, 2016", "MAY 26, 2016", "MAY 5, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "JUL 19, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "APR 27, 2016", "APR 27, 2016", "APR 28, 2016", "APR 25, 2016", "APR 21, 2016", "APR 20, 2016", "APR 19, 2016", "APR 18, 2016", "APR 18, 2016", "APR 14, 2016", "APR 26, 2016", "APR 13, 2016", "APR 13, 2016", "APR 13, 2016", "APR 12, 2016", "APR 12, 2016", "APR 12, 2016", "APR 11, 2016", "APR 13, 2016", "APR 11, 2016", "APR 8, 2016", "APR 7, 2016", "APR 7, 2016", "APR 5, 2016", "APR 4, 2016", "APR 4, 2016", "APR 11, 2016", "APR 11, 2016", "APR 8, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 24, 2016", "MAR 24, 2016", "MAR 31, 2016", "MAR 31, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 21, 2016", "MAR 21, 2016", "MAR 21, 2016", "MAR 24, 2016", "MAR 18, 2016", "MAR 17, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 18, 2016", "MAR 18, 2016", "MAR 14, 2016", "MAR 14, 2016", "MAR 14, 2016", "MAR 14, 2016", "MAR 11, 2016", "MAR 15, 2016", "MAR 11, 2016", "MAR 10, 2016", "MAR 10, 2016", "MAR 10, 2016", "MAR 9, 2016", "MAR 8, 2016", "MAR 7, 2016", "MAR 11, 2016", "MAR 11, 2016", "MAR 10, 2016", "MAR 10, 2016", "MAR 10, 2016", "MAR 3, 2016", "MAR 2, 2016", "MAR 7, 2016", "MAR 2, 2016", "MAR 1, 2016", "MAR 1, 2016", "MAR 1, 2016", "MAR 1, 2016", "FEB 29, 2016", "FEB 29, 2016", "MAR 2, 2016", "MAR 2, 2016", "FEB 29, 2016", "FEB 29, 2016", "FEB 29, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 29, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 25, 2016", "FEB 24, 2016", "FEB 24, 2016", "FEB 26, 2016", "FEB 23, 2016", "FEB 23, 2016", "FEB 22, 2016", "FEB 22, 2016", "FEB 19, 2016", "FEB 19, 2016", "FEB 19, 2016", "FEB 24, 2016", "FEB 23, 2016", "FEB 23, 2016", "FEB 18, 2016", "FEB 18, 2016", "FEB 18, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 18, 2016", "FEB 17, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 15, 2016", "FEB 15, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 15, 2016", "FEB 11, 2016", "FEB 15, 2016", "FEB 11, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 11, 2016", "FEB 8, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 4, 2016", "FEB 4, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 8, 2016", "FEB 5, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 3, 2016", "FEB 1, 2016", "FEB 1, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "FEB 2, 2016", "JAN 28, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 28, 2016", "JAN 22, 2016", "JAN 22, 2016", "JAN 22, 2016", "JAN 22, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 25, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 19, 2016", "JAN 19, 2016", "JAN 19, 2016", "JAN 18, 2016", "JAN 18, 2016", "JAN 20, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 13, 2016", "JAN 15, 2016", "JAN 13, 2016", "JAN 13, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 13, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 11, 2016", "JAN 11, 2016", "JAN 11, 2016", "JAN 11, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 5, 2016", "JAN 4, 2016", "DEC 30, 2015", "DEC 30, 2015", "DEC 29, 2015", "DEC 29, 2015", "JAN 11, 2016", "DEC 28, 2015", "DEC 28, 2015", "DEC 28, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 28, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 22, 2015", "DEC 22, 2015", "DEC 22, 2015", "DEC 22, 2015", "DEC 23, 2015", "DEC 21, 2015", "DEC 21, 2015", "DEC 18, 2015", "DEC 18, 2015", "DEC 18, 2015", "DEC 17, 2015", "DEC 17, 2015", "DEC 22, 2015", "DEC 21, 2015", "DEC 21, 2015", "DEC 15, 2015", "DEC 14, 2015", "DEC 14, 2015", "DEC 14, 2015", "DEC 16, 2015", "DEC 11, 2015", "DEC 10, 2015", "DEC 10, 2015", "DEC 10, 2015", "DEC 10, 2015", "DEC 9, 2015", "DEC 9, 2015", "DEC 11, 2015", "DEC 9, 2015", "DEC 9, 2015", "DEC 8, 2015", "DEC 8, 2015", "DEC 8, 2015", "DEC 8, 2015", "DEC 7, 2015", "DEC 9, 2015", "DEC 9, 2015", "DEC 9, 2015", "DEC 3, 2015", "DEC 3, 2015", "DEC 2, 2015", "DEC 2, 2015", "DEC 2, 2015", "DEC 7, 2015", "DEC 1, 2015", "DEC 1, 2015", "DEC 1, 2015", "NOV 30, 2015", "NOV 30, 2015", "NOV 26, 2015", "NOV 26, 2015", "DEC 1, 2015", "NOV 25, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 23, 2015", "NOV 23, 2015", "NOV 25, 2015", "NOV 23, 2015", "NOV 20, 2015", "NOV 20, 2015", "NOV 19, 2015", "NOV 19, 2015", "NOV 19, 2015", "NOV 17, 2015", "NOV 23, 2015", "NOV 17, 2015", "NOV 13, 2015", "NOV 13, 2015", "NOV 13, 2015", "NOV 11, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 17, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 9, 2015", "NOV 9, 2015", "NOV 10, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 5, 2015", "NOV 5, 2015", "NOV 9, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 2, 2015", "OCT 30, 2015", "OCT 30, 2015", "NOV 5, 2015", "OCT 30, 2015", "OCT 30, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 29, 2015", "OCT 28, 2015", "OCT 28, 2015", "OCT 30, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 26, 2015", "OCT 26, 2015", "OCT 26, 2015", "OCT 26, 2015", "OCT 27, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 20, 2015", "OCT 19, 2015", "OCT 19, 2015", "OCT 19, 2015", "OCT 23, 2015", "OCT 19, 2015", "OCT 16, 2015", "OCT 16, 2015", "OCT 16, 2015", "OCT 16, 2015", "OCT 16, 2015", "OCT 16, 2015", "OCT 19, 2015", "OCT 15, 2015", "OCT 15, 2015", "OCT 14, 2015", "OCT 14, 2015", "OCT 14, 2015", "OCT 13, 2015", "OCT 13, 2015", "OCT 15, 2015", "OCT 13, 2015", "OCT 13, 2015", "OCT 12, 2015", "OCT 12, 2015", "OCT 12, 2015", "OCT 12, 2015", "OCT 12, 2015", "OCT 13, 2015", "OCT 9, 2015", "OCT 8, 2015", "OCT 8, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 6, 2015", "OCT 9, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 6, 2015", "OCT 1, 2015", "OCT 1, 2015", "SEP 30, 2015", "SEP 30, 2015", "SEP 29, 2015", "SEP 29, 2015", "SEP 29, 2015", "OCT 1, 2015", "AUG 28, 2015", "AUG 27, 2015", "AUG 7, 2015", "DEC 10, 2014", "DEC 10, 2014", "MAY 22, 2014", "FEB 26, 2014", "SEP 24, 2015", "AUG 14, 2013", "AUG 9, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "FEB 26, 2014", "AUG 14, 2013", "JUL 31, 2013", "JUN 18, 2013", "JUN 18, 2013", "JUN 17, 2013", "JUN 17, 2013", "AUG 6, 2013", "JUN 13, 2013", "JUN 11, 2013", "JUN 11, 2013", "JUN 11, 2013", "JUN 10, 2013", "JUN 10, 2013", "JUN 6, 2013", "JUN 17, 2013", "JUN 5, 2013", "JUN 5, 2013", "JUN 5, 2013", "JUN 4, 2013", "JUN 3, 2013", "JUN 3, 2013", "MAY 31, 2013", "JUN 6, 2013", "MAY 24, 2013", "MAY 24, 2013", "MAY 24, 2013", "MAY 23, 2013", "MAY 23, 2013", "MAY 21, 2013", "MAY 20, 2013", "MAY 29, 2013", "MAY 15, 2013", "MAY 14, 2013", "MAY 10, 2013", "MAY 7, 2013", "MAY 2, 2013", "MAR 31, 2013", "JUN 4, 2012", "MAY 16, 2013", "MAY 25, 2012", "MAY 23, 2012", "MAY 17, 2012", "MAY 10, 2012", "MAY 8, 2012", "APR 25, 2012", "APR 20, 2012", "MAY 30, 2012", "APR 16, 2012", "FEB 15, 2011", "FEB 15, 2011", "APR 18, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q1-2020-earnings-call-transcript-2020-05-09", "https://www.nasdaq.com/articles/validea-benjamin-graham-strategy-daily-upgrade-report-3-18-2020-2020-03-18", "https://www.nasdaq.com/articles/anika-therapeutics-beats-revenue-and-earnings-estimates-2020-02-21", "https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q4-2019-earnings-call-transcript-2020-02-21", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-motley-fool-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q1-2020-earnings-call-transcript-2020-05-09", "https://www.nasdaq.com/articles/commit-to-buy-anika-therapeutics-at-%2455-earn-25-annualized-using-options-2019-12-11-0", "https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q3-2019-earnings-call-transcript-2019-10-25", "https://www.nasdaq.com/articles/why-anika-therapeutics-stock-crushed-it-today-2019-07-25", "https://www.nasdaq.com/articles/anika-therapeutics-blows-past-q2-earnings-estimates-2019-07-25", "https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q2-2019-earnings-call-transcript-2019-07-25", "https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q1-2019-earnings-call-transcript-2019-05-03", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-omcl-now-anik-2019-04-23", "https://www.nasdaq.com/articles/commit-to-buy-anika-therapeutics-at-%2455-earn-25-annualized-using-options-2019-12-11", "https://www.nasdaq.com/articles/anika-therapeutics-anik-q4-earnings-and-revenues-top-estimates-2019-02-21", "https://www.nasdaq.com/articles/analysts-estimate-anika-therapeutics-anik-to-report-a-decline-in-earnings%3A-what-to-look-2", "https://www.nasdaq.com/articles/alexions-ultomiris-gets-early-fda-nod-for-rare-blood-disorder-2018-12-24", "https://www.nasdaq.com/articles/agenus-stock-up-23-on-immuno-oncology-deal-with-gilead-2018-12-21", "https://www.nasdaq.com/articles/anik-vs.-rgen%3A-which-stock-should-value-investors-buy-now-2018-12-17", "https://www.nasdaq.com/articles/anika-therapeutics-enters-oversold-territory-2018-12-14", "https://www.nasdaq.com/articles/why-abeona-therapeutics-abeo-could-be-positioned-for-a-slump-2018-12-10", "https://www.nasdaq.com/articles/anika-therapeutics-anik-q4-2018-earnings-conference-call-transcript-2019-02-22", "https://www.nasdaq.com/articles/anika-therapeutics-inc-anik-q3-2018-earnings-conference-call-transcript-2018-10-24", "https://www.nasdaq.com/articles/anika-therapeutics-anik-q3-earnings-beat-estimates-2018-10-24", "https://www.nasdaq.com/articles/whats-in-store-for-anika-therapeutics-anik-in-q3-earnings-2018-10-22", "https://www.nasdaq.com/articles/anika-therapeutics-anik-q3-earnings-preview%3A-what-to-look-out-for-2018-10-17", "https://www.nasdaq.com/articles/ultragenyx-reports-top-line-data-from-gene-therapy-candidate-2018-09-28", "https://www.nasdaq.com/articles/amag-in-licenses-global-rights-to-orphan-drug-candidate-2018-09-27", "https://www.nasdaq.com/articles/verastem-out-licenses-china-rights-to-cancer-drug-copiktra-2018-09-26", "https://www.nasdaq.com/articles/anik-vs.-rgnx%3A-which-stock-should-value-investors-buy-now-2018-10-29", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-epizymes-lead-candidates-study-2018-09-25", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-sareptas-dmd-gene-therapy-program-2018-09-25", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-surges%3A-stock-moves-5.3-higher-2018-09-25", "https://www.nasdaq.com/articles/opko-health-opk-begins-rayaldee-phase-2-clinical-trial-2018-09-07", "https://www.nasdaq.com/articles/sesen-bio-sesn-soars%3A-stock-adds-6.3-in-session-2018-09-05", "https://www.nasdaq.com/articles/retrophin-rtrx-catches-eye%3A-stock-jumps-6.9-2018-09-04", "https://www.nasdaq.com/articles/sangamo-therapeutics-sgmo-looks-good%3A-stock-adds-8-in-session-2018-08-31", "https://www.nasdaq.com/articles/arena-arna-posts-favorable-top-line-data-on-pain-candidate-2018-09-25", "https://www.nasdaq.com/articles/anika-reports-top-line-data-from-cingal-study-shares-slump-2018-06-21", "https://www.nasdaq.com/articles/why-anika-therapeutics-inc-stock-sinking-2018-06-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-srpt-sldb-soar-on-positive-data-anik-ziop-crash-2018-06-20", "https://www.nasdaq.com/articles/why-pivotal-software-anika-therapeutics-and-oracle-slumped-today-2018-06-20", "https://www.nasdaq.com/articles/mid-afternoon-market-update-nasdaq-rises-1-naked-brand-group-shares-spike-higher-2018-06", "https://www.nasdaq.com/articles/weakness-seen-in-anika-therapeutics-anik-estimates%3A-should-you-stay-away-2018-05-18", "https://www.nasdaq.com/articles/notable-thursday-option-activity-anik-tree-coup-2018-05-03", "https://www.nasdaq.com/articles/2-biotech-stocks-tanked-week-can-they-recover-2018-06-22", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-april-20th-2018-04-20", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-april-16th-2018-04-16", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-april-6th-2018-04-06", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-april-2nd-2018-04-02", "https://www.nasdaq.com/articles/anika-therapeutics-enters-oversold-territory-2018-03-16", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-27th-2018-02-27", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-huntsman-earnings-top-estimates-2018-02-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-turns-positive-anika-therapeutics-shares-fall-following", "https://www.nasdaq.com/articles/mid-day-market-update-essendant-drops-after-q3-results-achieve-life-sciences-shares-climb", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-twitter-beats-q3-estimates-2017-10-26", "https://www.nasdaq.com/articles/mid-afternoon-market-update-buffalo-wild-wings-rises-upbeat-earnings-atossa-genetics", "https://www.nasdaq.com/articles/anika-anik-grows-in-orthopedic-medicines-on-positive-data-2017-08-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-valeant-pharmaceuticals-international-flexion", "https://www.nasdaq.com/articles/4-sell-ranked-drug-stocks-avoid-ahead-q2-earnings-2017-07-17", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-11th-2017-07-11", "https://www.nasdaq.com/articles/anika-therapeutics-receives-fda-nod-for-bone-repair-therapy-2018-01-03", "https://www.nasdaq.com/articles/health-care-sector-update-05222017-anik-2017-05-22", "https://www.nasdaq.com/articles/6-companies-offer-strong-value-potential-2nd-quarter-2017-2017-03-30", "https://www.nasdaq.com/articles/implied-volatility-surging-for-anika-therapeutics-anik-stock-options-2017-03-14", "https://www.nasdaq.com/articles/astrazeneca-azn-beats-on-q4-earnings-but-misses-on-sales-2017-02-03", "https://www.nasdaq.com/articles/amag-down-despite-positive-data-on-makena-auto-injector-2017-02-03", "https://www.nasdaq.com/articles/novo-nordisk-nvo-misses-q4-earnings-revenues-down-y-y-2017-02-03", "https://www.nasdaq.com/articles/biomarins-hemophilia-candidate-included-in-prime-initiative-2017-02-02", "https://www.nasdaq.com/articles/3-naked-puts-to-bank-%241000-plus-in-july-cash-2017-07-06", "https://www.nasdaq.com/articles/catabasis-hits-52-week-low-on-poor-dmd-drug-study-data-2017-02-02", "https://www.nasdaq.com/articles/abbvie-abbv-hcv-regimen-gets-priority-review-in-canada-2017-02-02", "https://www.nasdaq.com/articles/eli-lilly-lly-misses-on-q4-earnings-beats-on-revenues-2017-01-31", "https://www.nasdaq.com/articles/allergan-agn-avycaz-label-to-include-new-phase-iii-data-2017-01-31", "https://www.nasdaq.com/articles/exelixis-inks-partnership-with-takeda-for-cabometyx-in-japan-2017-01-31", "https://www.nasdaq.com/articles/endos-endp-ephedrine-sulfate-injection-gets-fda-approval-2017-01-31", "https://www.nasdaq.com/articles/celgene-celg-gets-favorable-chmp-opinion-for-revlimid-2017-01-30", "https://www.nasdaq.com/articles/novartis-nvs-votubia-gets-eu-approval-for-label-expansion-2017-02-02", "https://www.nasdaq.com/articles/endo-endp-restructures-branded-pharmaceutical-unit-revised-2017-01-30", "https://www.nasdaq.com/articles/pfizer-pfe-c.-difficile-vaccine-positive-in-phase-ii-study-2017-01-27", "https://www.nasdaq.com/articles/endo-endp-restructures-its-branded-pharmaceutical-unit-2017-01-27", "https://www.nasdaq.com/articles/jj-to-acquire-actelion-for-%2430b%3A-is-it-a-strategic-fit-2017-01-27", "https://www.nasdaq.com/articles/astrazenecas-symbicort-granted-pediatric-exclusivity-by-fda-2017-01-27", "https://www.nasdaq.com/articles/immunogen-doses-first-patient-in-ovarian-cancer-drug-study-2017-01-27", "https://www.nasdaq.com/articles/abbvie-abbv-q4-earnings-meet-estimates-revenues-lag-2017-01-27", "https://www.nasdaq.com/articles/novo-nordisk-inks-diabetes-deal-with-university-of-oxford-2017-01-30", "https://www.nasdaq.com/articles/celgene-celg-misses-on-earnings-revenues-keeps-view-2017-01-26", "https://www.nasdaq.com/articles/bristol-myers-bmy-misses-on-q4-earnings-beats-on-sales-2017-01-26", "https://www.nasdaq.com/articles/abbvies-hcv-regimen-okayed-for-accelerated-assessment-2017-01-25", "https://www.nasdaq.com/articles/lillys-elanco-unit-aratana-launch-veterinary-pain-drug-2017-01-25", "https://www.nasdaq.com/articles/endo-endp-settles-disputes-with-federal-trade-commission-2017-01-24", "https://www.nasdaq.com/articles/eagle-pharmaceuticals-wraps-up-ryanodex-nda-submission-2017-01-24", "https://www.nasdaq.com/articles/marinus-releases-positive-preliminary-data-from-cdkl5-study-2017-01-24", "https://www.nasdaq.com/articles/vertex-pharmas-vrtx-q4-earnings-sales-beat-stock-up-2017-01-26", "https://www.nasdaq.com/articles/minerva-presents-additional-data-from-schizophrenia-drug-2017-01-23", "https://www.nasdaq.com/articles/concerts-cnce-ctp-656-gets-orphan-drug-status-in-u.s.-2017-01-23", "https://www.nasdaq.com/articles/bristol-myers-settles-litigation-with-merck-for-keytruda-2017-01-23", "https://www.nasdaq.com/articles/bristol-myers-to-not-seek-accelerated-approval-for-opdivoyervoy-2017-01-20", "https://www.nasdaq.com/articles/aduro-adro-inks-license-agreement-with-stanford-university-2017-01-20", "https://www.nasdaq.com/articles/shires-shpg-adhd-candidates-nda-accepted-by-fda-2017-01-20", "https://www.nasdaq.com/articles/apricus-apri-stock-gains-on-vitaros-approval-in-mexico-2017-01-19", "https://www.nasdaq.com/articles/healthinvest-partners-ab-buys-gilead-sciences-inc-mckesson-corp-syneron-medical-ltd-sells", "https://www.nasdaq.com/articles/bioblast-orpn-sca3-drug-favorable-in-phase-iia-study-2017-01-19", "https://www.nasdaq.com/articles/mallinckrodt-to-pay-%24100m-fine-to-ftc-for-questcor-matter-2017-01-19", "https://www.nasdaq.com/articles/concert-offers-update-on-cystic-fibrosis-drug-stock-down-2017-01-18", "https://www.nasdaq.com/articles/sanofi-diabetes-drug-suliqua-wins-eu-marketing-approval-2017-01-18", "https://www.nasdaq.com/articles/jazz-begins-phase-iii-study-for-label-expansion-of-defitelio-2017-01-18", "https://www.nasdaq.com/articles/astrazeneca-offers-update-on-immuno-oncology-program-2017-01-18", "https://www.nasdaq.com/articles/agenus-nci-ink-deal-to-evaluate-prophage-keytruda-combo-2017-01-18", "https://www.nasdaq.com/articles/tevas-teva-pain-drug-vantrela-er-receives-fda-approval-2017-01-19", "https://www.nasdaq.com/articles/benitec-stock-up-on-orphan-drug-status-for-bb-301-in-eu-2017-01-18", "https://www.nasdaq.com/articles/biogen-to-pay-%241.25b-to-forward-pharma-in-tecfidera-lawsuit-2017-01-18", "https://www.nasdaq.com/articles/allergans-uterine-fibroids-candidate-positive-in-phase-iii-2017-01-18", "https://www.nasdaq.com/articles/whats-behind-clovis-clvs-one-year-rally-of-146.3-2017-01-17", "https://www.nasdaq.com/articles/biogens-multiple-sclerosis-franchise-to-drive-growth-in-2017-2017-01-17", "https://www.nasdaq.com/articles/steven-romick-spots-next-area-investment-interest-health-care-2017-01-13", "https://www.nasdaq.com/articles/pluristem-psti-intermittent-claudication-study-enrolled-2017-01-13", "https://www.nasdaq.com/articles/kura-oncology-starts-dosing-patients-in-phase-ii-cmml-study-2017-01-18", "https://www.nasdaq.com/articles/benitec-stock-up-on-orphan-drug-status-for-bb-301-in-eu-2017-01-18", "https://www.nasdaq.com/articles/amag-palatin-ink-deal-to-focus-on-female-sexual-disorder-2017-01-10", "https://www.nasdaq.com/articles/abbvies-hcv-combo-favorable-in-japanese-phase-iii-study-2017-01-10", "https://www.nasdaq.com/articles/ionis-novartis-ink-deal-to-focus-on-cardiovascular-treatments-2017-01-09", "https://www.nasdaq.com/articles/vertex-pharma-issues-disappointing-2017-orkambi-outlook-2017-01-09", "https://www.nasdaq.com/articles/genocea-stock-up-on-positive-genital-herpes-infections-data-2017-01-06", "https://www.nasdaq.com/articles/biogen-licenses-amunixs-xten-technology-for-factor-ix-drug-2017-01-06", "https://www.nasdaq.com/articles/novartis-to-conduct-trial-on-obese-type-ii-diabetes-patients-2017-01-13", "https://www.nasdaq.com/articles/ultragenyxs-rare-krn23-accepted-for-review-in-the-eu-2017-01-06", "https://www.nasdaq.com/articles/argos-therapeutics-args-looks-good%3A-stock-rises-by-5-2017-01-06", "https://www.nasdaq.com/articles/arena-eisai-modify-marketing-supply-agreement-for-belviq-2017-01-05", "https://www.nasdaq.com/articles/spark-therapeutics-gets-%2415m-milestone-payment-from-pfizer-2017-01-05", "https://www.nasdaq.com/articles/alexion-alxn-stock-up-on-10q-filing-2016-view-retained-2017-01-05", "https://www.nasdaq.com/articles/clovis-declares-pricing-of-upsized-offering-of-common-stock-2017-01-04", "https://www.nasdaq.com/articles/alexion-alxn%3A-will-the-stock-continue-to-suffer-in-2017-2017-01-04", "https://www.nasdaq.com/articles/halozyme-halo-up-on-positive-phase-ii-data-on-pegph20-2017-01-06", "https://www.nasdaq.com/articles/ultragenyxs-rare-krn23-accepted-for-review-in-the-eu-2017-01-06", "https://www.nasdaq.com/articles/neothetics-neot-begins-phase-ii-study-on-lead-candidate-2016-12-28", "https://www.nasdaq.com/articles/horizons-rare-disease-drug-quinsair-launched-in-canada-2016-12-27", "https://www.nasdaq.com/articles/celgenes-otezla-gains-positive-recommendation-from-nice-2016-12-23", "https://www.nasdaq.com/articles/acadia-phase-ii-alzheimers-drug-hits-primary-endpoint-2016-12-21", "https://www.nasdaq.com/articles/3-reasons-why-anika-therapeutics-anik-is-a-great-momentum-stock-2016-12-20", "https://www.nasdaq.com/articles/is-vertex-pharma-vrtx-poised-for-a-turnaround-in-2017-2017-01-03", "https://www.nasdaq.com/articles/how-anika-therapeutics-anik-stock-stands-out-in-a-strong-industry-2016-12-14", "https://www.nasdaq.com/articles/pfizer-leukemia-drug-meets-primary-endpoint-in-phase-iii-2016-12-06", "https://www.nasdaq.com/articles/roche-presents-positive-follicular-lymphoma-data-on-gazvya-2016-12-06", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2016-12-01", "https://www.nasdaq.com/articles/aimmune-closes-enrolment-in-phase-iii-peanut-allergy-study-2016-11-30", "https://www.nasdaq.com/articles/phaserx-soars-on-orphan-drug-status-for-rare-liver-disease-2016-11-30", "https://www.nasdaq.com/articles/foamix-completes-enrolment-in-phase-iii-acne-drug-studies-2016-11-30", "https://www.nasdaq.com/articles/abbvie-abbv-submits-nda-for-next-gen-hcv-combo-in-us-2016-12-20", "https://www.nasdaq.com/articles/jazz-completes-patient-enrollment-in-jzp-110-narcolepsy-trial-2016-11-29", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-chemours-matador-resources-best-buy-anika-therapeutics-and", "https://www.nasdaq.com/articles/navidea-inks-deal-to-to-sell-lymphoseek-to-cardinal-health-2016-11-25", "https://www.nasdaq.com/articles/opko-health-opk-launches-kidney-drug-rayaldee-in-u.s.-2016-11-25", "https://www.nasdaq.com/articles/merck-mrk-announces-2.2-increase-in-quarterly-dividend-2016-11-24", "https://www.nasdaq.com/articles/glaxo-nucala-favorable-in-rare-vasculitis-disease-study-2016-11-24", "https://www.nasdaq.com/articles/junos-rocket-study-on-clinical-hold-again-shares-down-2016-11-24", "https://www.nasdaq.com/articles/cytori-scleroderma-study-two-year-follow-up-data-published-2016-11-30", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-eu-approval-for-label-expansion-2016-11-23", "https://www.nasdaq.com/articles/astrazeneca%3A-fda-lifts-hold-on-head-neck-cancer-trials-2016-11-23", "https://www.nasdaq.com/articles/forget-earnings-growth-focus-on-beat-with-these-5-stocks-2016-11-23", "https://www.nasdaq.com/articles/ligands-partner-retrophin-provides-new-data-on-sparsentan-2016-11-22", "https://www.nasdaq.com/articles/sanofi-sny-soliqua-approved-for-type-2-diabetes-in-adults-2016-11-22", "https://www.nasdaq.com/articles/allergans-fibristal-approved-in-canada-for-label-expansion-2016-11-22", "https://www.nasdaq.com/articles/apricus-biosciences-aims-to-resubmit-vitaros-nda-in-2017-2016-11-21", "https://www.nasdaq.com/articles/novo-nordisks-diabetes-combination-drug-gets-fdas-nod-2016-11-23", "https://www.nasdaq.com/articles/endo-reports-positive-cellulite-treatment-data-on-xiaflex-2016-11-18", "https://www.nasdaq.com/articles/keryx-kerx-stock-up-on-positive-phase-iii-auryxia-data-2016-11-18", "https://www.nasdaq.com/articles/regeneron-sanofis-praluent-cv-outcomes-study-to-continue-2016-11-18", "https://www.nasdaq.com/articles/sanofi-regeneron-present-sarilumab-data-at-acr-meeting-2016-11-18", "https://www.nasdaq.com/articles/shire-launches-cuvitru-in-u.s.-for-primary-immunodeficiency-2016-11-17", "https://www.nasdaq.com/articles/glaxo-gsk-presents-phase-iii-data-on-sirukumab-benlysta-2016-11-17", "https://www.nasdaq.com/articles/surmodics-srdx-beats-q4-earnings-revenues-estimates-2016-11-17", "https://www.nasdaq.com/articles/novartis-amgen-migraine-drug-positive-in-phase-iii-study-2016-11-18", "https://www.nasdaq.com/articles/endo-reports-positive-cellulite-treatment-data-on-xiaflex-2016-11-18", "https://www.nasdaq.com/articles/keryx-kerx-stock-up-on-positive-phase-iii-auryxia-data-2016-11-18", "https://www.nasdaq.com/articles/merck-kgaas-mkgaf-q3-earnings-and-sales-increase-y-y-2016-11-16", "https://www.nasdaq.com/articles/ionis-ions-offers-positive-interim-data-on-lipid-candidate-2016-11-16", "https://www.nasdaq.com/articles/pfizer-reports-phase-iii-psoriatic-arthritis-data-on-xeljanz-2016-11-16", "https://www.nasdaq.com/articles/novartis-offers-positive-data-on-cardiovascular-drug-entresto-2016-11-16", "https://www.nasdaq.com/articles/spectrum-sppi-reports-narrower-than-expected-q3-loss-2016-11-15", "https://www.nasdaq.com/articles/gilead-reports-phase-iii-myelofibrosis-data-on-momelotinib-2016-11-17", "https://www.nasdaq.com/articles/repros-rprx-reports-positive-top-line-data-on-proellex-2016-11-15", "https://www.nasdaq.com/articles/amgen-presents-osteoporosis-data-parsabiv-approved-in-eu-2016-11-14", "https://www.nasdaq.com/articles/masimo-masi-gets-%244.95-million-gates-foundation-grant-2016-11-14", "https://www.nasdaq.com/articles/pra-health-sciences-prah-announces-secondary-offering-2016-11-14", "https://www.nasdaq.com/articles/alexion-alxn-offers-long-term-phase-iii-data-on-kanuma-2016-11-14", "https://www.nasdaq.com/articles/gilead-gild-hbv-drug-vemlidy-gets-positive-chmp-opinion-2016-11-14", "https://www.nasdaq.com/articles/lemaitre-lmat-hits-a-52-week-high-on-strategic-buyout-2016-11-14", "https://www.nasdaq.com/articles/celldex-stock-up-on-positive-data-on-new-cancer-candidate-2016-11-15", "https://www.nasdaq.com/articles/lilys-jardiance-effective-in-lowering-cardiovascular-death-2016-11-14", "https://www.nasdaq.com/articles/abbvies-abbv-humira-wins-chmp-backing-for-expanded-use-2016-11-14", "https://www.nasdaq.com/articles/sanofi-sny-diabetes-drug-toujeo-positive-in-pk-pd-study-2016-11-14", "https://www.nasdaq.com/articles/vivus-vvus-reports-narrower-than-expected-loss-in-q3-2016-11-12", "https://www.nasdaq.com/articles/baxters-sigma-spectrum-infusion-system-gets-klas-award-2016-11-11", "https://www.nasdaq.com/articles/lemaitre-vascular-buys-restore-flow-allografts-for-%2414m-2016-11-11", "https://www.nasdaq.com/articles/astrazeneca-azn-beats-on-q3-earnings-sales-slow-down-2016-11-11", "https://www.nasdaq.com/articles/bristol-myers-offers-updates-from-opdivo-combination-trials-2016-11-14", "https://www.nasdaq.com/articles/intrexon-xon-reports-in-line-loss-in-q3-revenues-miss-2016-11-11", "https://www.nasdaq.com/articles/vivus-vvus-reports-narrower-than-expected-loss-in-q3-2016-11-11", "https://www.nasdaq.com/articles/kite-pharma-q3-loss-betters-estimate-kte-c19-on-track-2016-11-10", "https://www.nasdaq.com/articles/dexcom-dxcm-incurs-wider-loss-in-q3-beats-on-revenue-2016-11-10", "https://www.nasdaq.com/articles/perrigo-prgo-beats-on-q3-earnings-revenues-view-intact-2016-11-10", "https://www.nasdaq.com/articles/keryx-kerx-q3-loss-wider-than-expected-restores-supply-2016-11-10", "https://www.nasdaq.com/articles/endocyte-ecyt-stock-up-on-lower-than-expected-q3-loss-2016-11-11", "https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q3-2016-11-11", "https://www.nasdaq.com/articles/intrexon-xon-reports-in-line-loss-in-q3-revenues-miss-2016-11-11", "https://www.nasdaq.com/articles/mylan-myl-q3-earnings-revenues-miss-on-epipen-woes-2016-11-10", "https://www.nasdaq.com/articles/puma-pbyi-posts-wider-loss-in-q3-neratinib-in-focus-2016-11-10", "https://www.nasdaq.com/articles/biodelivery-bdsi-reports-wider-than-expected-loss-in-q3-2016-11-10", "https://www.nasdaq.com/articles/impax-ipxl-down-on-q3-earnings-sales-miss-cuts-view-2016-11-10", "https://www.nasdaq.com/articles/inovio-ino-q3-loss-wider-than-expected-revenues-beat-2016-11-10", "https://www.nasdaq.com/articles/trovagene-trov-reports-wider-than-expected-loss-in-q3-2016-11-10", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-mcdermott-international-nvidia-nxstage-medical-melco-crown", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q3-earnings-top-sales-lag-estimates-2016-11-09", "https://www.nasdaq.com/articles/how-anika-therapeutics-anik-stock-stands-out-in-a-strong-industry-2016-11-09", "https://www.nasdaq.com/articles/conatus-cnat-reports-narrower-than-expected-loss-in-q3-2016-11-09", "https://www.nasdaq.com/articles/ophthotech-opht-q3-loss-wider-than-expected-sales-fall-2016-11-09", "https://www.nasdaq.com/articles/valeant-pharma-vrx-q3-earnings-miss-slashes-guidance-2016-11-09", "https://www.nasdaq.com/articles/repros-rprx-loss-narrower-y-y-in-q3-pipeline-in-focus-2016-11-09", "https://www.nasdaq.com/articles/mannkind-mnkd-q3-earnings-beat-inks-deal-with-sanofi-2016-11-10", "https://www.nasdaq.com/articles/kite-pharma-kite-looks-good%3A-stock-adds-7-in-session-2016-11-08", "https://www.nasdaq.com/articles/arena-arna-q3-loss-lower-than-expected-revenues-rise-2016-11-08", "https://www.nasdaq.com/articles/emergent-ebs-beats-earnings-revenue-estimates-in-q3-2016-11-08", "https://www.nasdaq.com/articles/on-the-lookout-for-earnings-beat-5-top-picks-2016-11-08", "https://www.nasdaq.com/articles/nektar-nktr-stock-up-on-narrower-than-expected-q3-loss-2016-11-08", "https://www.nasdaq.com/articles/should-you-get-rid-of-capital-senior-living-csu-now-2016-11-07", "https://www.nasdaq.com/articles/aimmune-therapeutics-aimt-catches-eye%3A-stock-jumps-8.9-2016-11-07", "https://www.nasdaq.com/articles/endo-endp-q3-earnings-revenues-beat-view-intact-2016-11-08", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q3-earnings-lag-revenues-fall-y-y-2016-11-07", "https://www.nasdaq.com/articles/amag-pharma-amag-q3-earnings-up-y-y-revenues-beat-2016-11-07", "https://www.nasdaq.com/articles/what-makes-innoviva-inva-a-strong-sell-2016-11-04", "https://www.nasdaq.com/articles/ironwood-irwd-posts-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/radius-health-rdus-q3-loss-match-estimates-wider-y-y-2016-11-04", "https://www.nasdaq.com/articles/pacira-pcrx-misses-q3-earnings-estimates-beats-on-sales-2016-11-03", "https://www.nasdaq.com/articles/amerisourcebergen-abc-q4-earnings-top-revenues-lag-2016-11-02", "https://www.nasdaq.com/articles/achillion-achn-reports-narrower-than-expected-q3-loss-2016-11-07", "https://www.nasdaq.com/articles/integra-iart-catches-eye%3A-stock-adds-6-in-session-2016-10-31", "https://www.nasdaq.com/articles/teva-to-divest-actavis-generics-uk-ireland-operations-2016-10-06", "https://www.nasdaq.com/articles/alnylam-alny-discontinues-phase-iii-study-on-revusiran-2016-10-06", "https://www.nasdaq.com/articles/cara-therapeutics-cara-catches-eye%3A-stock-moves-up-12-2016-10-06", "https://www.nasdaq.com/articles/eli-lilly-to-buy-boehringers-vetmedica-pet-vaccines-unit-2016-10-06", "https://www.nasdaq.com/articles/roche-rhhby-actemra-gets-breakthrough-therapy-status-2016-10-05", "https://www.nasdaq.com/articles/bayer-bayry-closes-registration-process-for-kyleena-in-eu-2016-10-05", "https://www.nasdaq.com/articles/corcept-cort-beats-on-q3-earnings-lifts-sales-guidance-2016-11-02", "https://www.nasdaq.com/articles/ocular-begins-enrollment-in-phase-iii-trial-on-glaucoma-drug-2016-10-05", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-anika-therapeutics-advanced-micro-devices-edwards", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vivus-geron-achillion-pharmaceuticals-anika", "https://www.nasdaq.com/articles/editas-medicine-edit-catches-eye%3A-stock-moves-up-11-2016-10-05", "https://www.nasdaq.com/articles/amgen-announces-publication-of-blincyto-phase-i-ii-data-2016-10-04", "https://www.nasdaq.com/articles/jazz-initiates-rolling-nda-for-leukemia-candidate-vyxeos-2016-10-04", "https://www.nasdaq.com/articles/alkermes-commences-metabolic-study-on-schizophrenia-drug-2016-10-04", "https://www.nasdaq.com/articles/theravance-tbph-starts-dosing-in-ulcerative-colitis-study-2016-10-05", "https://www.nasdaq.com/articles/get-ready-be-surprised-earnings-season-2016-10-04", "https://www.nasdaq.com/articles/emergent-ebs-stock-up-on-multi-year-nuthrax-vaccine-deal-2016-10-03", "https://www.nasdaq.com/articles/regenerons-eylea-rinucumab-combination-data-disappoints-2016-10-03", "https://www.nasdaq.com/articles/abbvie%3A-hcv-regimen-obtains-breakthrough-therapy-status-2016-10-03", "https://www.nasdaq.com/articles/horizon-pharma-express-scripts-to-settle-rebate-litigation-2016-10-03", "https://www.nasdaq.com/articles/immunogen-to-cut-workforce-by-17-for-long-term-growth-2016-10-03", "https://www.nasdaq.com/articles/endo-international-reports-positive-phase-ii-data-on-xiaflex-2016-10-03", "https://www.nasdaq.com/articles/teva-boosts-generic-business-with-allergan-anda-takeover-2016-10-04", "https://www.nasdaq.com/articles/pain-therapeutics-ptie-down-crl-chronic-pain-drug-2016-09-28", "https://www.nasdaq.com/articles/jazz-pharma-closes-enrollment-in-osa-drug-phase-iii-trial-2016-09-28", "https://www.nasdaq.com/articles/acelrx-acrx-initiates-phase-iii-iap312-study-on-zalviso-2016-09-28", "https://www.nasdaq.com/articles/amgens-multiple-myeloma-drug-kyprolis-fails-in-phase-iii-2016-09-28", "https://www.nasdaq.com/articles/myriad-genetics-to-present-myrisk-data-at-seattle-conference-2016-09-28", "https://www.nasdaq.com/articles/bristol-myers-nektar-tie-up-for-opdivo-nktr-214-combo-2016-09-28", "https://www.nasdaq.com/articles/summit-smmt%3A-rare-pediatric-disease-status-for-dmd-drug-2016-09-28", "https://www.nasdaq.com/articles/intra-cellular-reports-poor-phase-iii-schizophrenia-data-2016-09-29", "https://www.nasdaq.com/articles/ionis-biogen-complete-nusinersen-nda-submission-in-u.s.-2016-09-27", "https://www.nasdaq.com/articles/amgen-ucbs-bla-for-osteoporosis-drug-accepted-in-the-u.s.-2016-09-27", "https://www.nasdaq.com/articles/novartis-ilaris-approved-for-extended-use-in-periodic-fever-2016-09-26", "https://www.nasdaq.com/articles/achillion-jj-hcv-triple-combination-drug-data-presented-2016-09-26", "https://www.nasdaq.com/articles/glaxo-jj-file-bla-for-rheumatoid-arthritis-drug-in-the-u.s.-2016-09-26", "https://www.nasdaq.com/articles/abbvie-abbv-hcv-combination-drug-positive-in-phase-iiib-2016-09-26", "https://www.nasdaq.com/articles/ligand-inks-cns-license-agreement-with-seelos-therapeutics-2016-09-23", "https://www.nasdaq.com/articles/abbvie-abbv-files-snda-for-blood-cancer-drug-imbruvica-2016-09-27", "https://www.nasdaq.com/articles/the-medicines-co.-to-get-barda-funding-for-infection-drugs-2016-09-22", "https://www.nasdaq.com/articles/gilead-to-stop-gs-5745-development-for-ulcerative-colitis-2016-09-22", "https://www.nasdaq.com/articles/puma-pbyi-neratinibs-nda-accepted-for-review-stock-up-2016-09-21", "https://www.nasdaq.com/articles/amgen-amgn-repatha-meets-endpoints-in-phase-iii-study-2016-09-21", "https://www.nasdaq.com/articles/regeneron-teva-collaborate-to-develop-chronic-pain-drug-2016-09-21", "https://www.nasdaq.com/articles/biodelivery-bunavail-gets-better-managed-care-positioning-2016-09-20", "https://www.nasdaq.com/articles/sarepta-stock-nearly-doubles-on-fda-approval-for-dmd-drug-2016-09-20", "https://www.nasdaq.com/articles/novartis-nvs-zykadia-positive-in-phase-iii-ascend-4-study-2016-09-23", "https://www.nasdaq.com/articles/celgene-presents-efficacy-safety-phase-ii-ozanimod-data-2016-09-20", "https://www.nasdaq.com/articles/vical-slumps-cytomegalovirus-vaccine-fails-in-phase-ii-study-2016-09-20", "https://www.nasdaq.com/articles/ligand-lgnd-inks-deal-with-teneobio-for-omniab-technology-2016-09-19", "https://www.nasdaq.com/articles/qiagen%3A-molecular-diagnostics-expansion-plans-on-track-2016-09-16", "https://www.nasdaq.com/articles/novavax-tanks-rsv-f-vaccine-disappoints-in-two-studies-2016-09-16", "https://www.nasdaq.com/articles/teva-intel-tie-up-for-huntingtons-disease-technology-platform-2016-09-16", "https://www.nasdaq.com/articles/glaxo-gsk-publishes-phase-iii-data-on-shingles-vaccine-2016-09-15", "https://www.nasdaq.com/articles/bayer-bayry-strives-for-increased-sales-earnings-growth-2016-09-20", "https://www.nasdaq.com/articles/aerie-aeri-stock-up-on-positive-phase-iii-data-on-roclatan-2016-09-15", "https://www.nasdaq.com/articles/spectrum-sppi-down-qapzola-fails-to-impress-fda-panel-2016-09-15", "https://www.nasdaq.com/articles/ligand-lgnd-commences-phase-ii-type-ii-diabetes-study-2016-09-14", "https://www.nasdaq.com/articles/will-bayer-bayry-raise-its-monsanto-buyout-offer-again-2016-09-14", "https://www.nasdaq.com/articles/repros-seeks-eu-approval-for-secondary-hypogonadism-drug-2016-09-13", "https://www.nasdaq.com/articles/celgenes-crohns-disease-drug-positive-in-phase-ib-study-2016-09-13", "https://www.nasdaq.com/articles/jj-files-for-single-tablet-regimen-of-hiv-drug-prezista-in-eu-2016-09-13", "https://www.nasdaq.com/articles/bayer-to-boost-agriculture-suite-with-%2466b-monsanto-buyout-2016-09-15", "https://www.nasdaq.com/articles/aerie-aeri-stock-up-on-positive-phase-iii-data-on-roclatan-2016-09-15", "https://www.nasdaq.com/articles/spectrum-sppi-down-qapzola-fails-to-impress-fda-panel-2016-09-15", "https://www.nasdaq.com/articles/ligand-lgnd-commences-phase-ii-type-ii-diabetes-study-2016-09-14", "https://www.nasdaq.com/articles/will-bayer-bayry-raise-its-monsanto-buyout-offer-again-2016-09-14", "https://www.nasdaq.com/articles/clovis-rucaparib-not-to-face-fda-advisory-panel-stock-up-2016-09-09", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-phase-i-data-on-aln-as1-2016-09-08", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-proellex-positive-in-phase-ii-2016-09-08", "https://www.nasdaq.com/articles/horizon-hznp-to-acquire-raptor-for-%24800m-stock-soars-2016-09-13", "https://www.nasdaq.com/articles/bristol-myers-orencia-gains-eu-approval-for-expanded-use-2016-09-07", "https://www.nasdaq.com/articles/biomarins-bmrn-brineura-review-period-extended-by-fda-2016-09-07", "https://www.nasdaq.com/articles/colucid-hits-52-week-high-on-positive-data-on-migraine-drug-2016-09-07", "https://www.nasdaq.com/articles/glaxo-bexsero-meningitis-b-immunization-shows-positive-data-2016-09-06", "https://www.nasdaq.com/articles/masimo-amends-nellcors-pulse-oximetry-royalty-agreement-2016-09-06", "https://www.nasdaq.com/articles/bayer-bayry-raises-offer-to-purchase-monsanto-yet-again-2016-09-06", "https://www.nasdaq.com/articles/astrazeneca-azn-presents-benralizumab-phase-iii-data-2016-09-06", "https://www.nasdaq.com/articles/ligand-retrophin-rare-disease-drug-positive-in-phase-ii-2016-09-08", "https://www.nasdaq.com/articles/novo-nordisks-ideglira-review-period-extended-in-the-u.s.-2016-09-05", "https://www.nasdaq.com/articles/merck-stops-development-of-odanacatib-for-osteoporosis-2016-09-05", "https://www.nasdaq.com/articles/arena-arna-beacon-discovery-to-boost-research-platform-2016-09-02", "https://www.nasdaq.com/articles/biogen-biib-aducanumab-gets-fast-track-status-in-the-u.s.-2016-09-02", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-sodastream-international-childrens-place-quidel-mks", "https://www.nasdaq.com/articles/amgen-gets-fda-approval-for-label-expansion-of-blincyto-2016-09-02", "https://www.nasdaq.com/articles/allergan-adamas-agree-to-settle-namzaric-patent-litigation-2016-09-01", "https://www.nasdaq.com/articles/myriad-genetics-adds-assurex-health-grows-in-neuroscience-2016-09-06", "https://www.nasdaq.com/articles/get-nice-earnings-surprise-with-these-5-stocks-2016-09-01", "https://www.nasdaq.com/articles/rigel-rigl-stock-up-on-positive-phase-iii-fostamatinib-data-2016-08-31", "https://www.nasdaq.com/articles/cti-biopharma-reports-mixed-pacritinib-study-data-stock-up-2016-08-30", "https://www.nasdaq.com/articles/alexions-gvhd-candidate-gets-orphan-drug-status-in-the-eu-2016-08-30", "https://www.nasdaq.com/articles/amgen-amgn-reports-positive-data-on-prolia-and-repatha-2016-08-30", "https://www.nasdaq.com/articles/macrocure-stock-up-on-merger-deal-with-leap-therapeutics-2016-08-30", "https://www.nasdaq.com/articles/weakness-seen-in-keryx-biopharmaceuticals-kerx-estimates%3A-should-you-stay-away-2016-08-29", "https://www.nasdaq.com/articles/amarin-amrn-ends-patient-randomization-in-vascepa-study-2016-09-01", "https://www.nasdaq.com/articles/illumina-keen-on-genome-network-growth-global-expansion-2016-08-26", "https://www.nasdaq.com/articles/amgen-gets-crl-for-secondary-hyperparathyroidism-drug-2016-08-25", "https://www.nasdaq.com/articles/gilead-gild-truvada-gets-eu-approval-for-label-expansion-2016-08-23", "https://www.nasdaq.com/articles/xenetics-ind-to-start-phase-ii-virexxa-study-accepted-in-u.s.-2016-08-22", "https://www.nasdaq.com/articles/portola-indexxas-regulatory-application-validated-in-the-eu-2016-08-22", "https://www.nasdaq.com/articles/teva-cinqaero-gets-eu-nod-for-severe-eosinophilic-asthma-2016-08-19", "https://www.nasdaq.com/articles/aclaris-acrs-common-warts-candidate-positive-in-phase-ii-2016-08-19", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-catches-eye%3A-stocks-up-20-2016-08-26", "https://www.nasdaq.com/articles/illumina-keen-on-genome-network-growth-global-expansion-2016-08-26", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-anika-therapeutics-anik-stock-2016-08-17", "https://www.nasdaq.com/articles/actelion-aliof-uptravi-approved-for-pah-in-switzerland-2016-08-17", "https://www.nasdaq.com/articles/inovio-ino-veterinary-vaccine-rights-licensed-to-plumbline-2016-08-17", "https://www.nasdaq.com/articles/radius-rdus-osteoporosis-drug-positive-in-phase-iii-study-2016-08-17", "https://www.nasdaq.com/articles/align-technologys-invisalign-dependence%3A-boon-or-curse-2016-08-17", "https://www.nasdaq.com/articles/fda-oks-edwards-lifesciences-sapien-3-for-extended-use-2016-08-19", "https://www.nasdaq.com/articles/repros-presents-6-month-interim-data-enclomiphene-2016-08-16", "https://www.nasdaq.com/articles/ucb-epilepsy-drug-vimpats-patent-validated-by-u.s.-court-2016-08-16", "https://www.nasdaq.com/articles/vertex-vrtx-stop-vx-661-ivacaftor-study-stock-down-2016-08-16", "https://www.nasdaq.com/articles/myriad-genetics%3A-q4-hit-by-low-test-revenues-gross-margin-2016-08-16", "https://www.nasdaq.com/articles/cormedix-crmd-shows-strength%3A-stock-moves-up-24.8-2016-08-12", "https://www.nasdaq.com/articles/allergan-agn-tops-q2-earnings-revises-16-outlook-2016-08-08", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-q2-earnings-revenues-up-y-y-2016-08-08", "https://www.nasdaq.com/articles/fda-approves-edwards-lifesciences-intuity-elite-heart-valve-2016-08-17", "https://www.nasdaq.com/articles/agios-agio-q2-loss-wider-than-expected-pipeline-in-focus-2016-08-05", "https://www.nasdaq.com/articles/aveo-aveo-reports-a-wider-loss-in-q2-tivozanib-in-focus-2016-08-05", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-narrower-than-expected-loss-in-q2-2016-08-05", "https://www.nasdaq.com/articles/radius-health-rdus-reports-wider-than-expected-q2-loss-2016-08-05", "https://www.nasdaq.com/articles/merck-kgaa-mkgaf-q2-earnings-fall-guides-up-on-sales-2016-08-05", "https://www.nasdaq.com/articles/array-biopharma-arry-in-focus%3A-stock-moves-9.3-higher-2016-08-05", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-catches-eye%3A-stock-jumps-6.9-2016-08-05", "https://www.nasdaq.com/articles/biomarin-bmrn-posts-narrower-q2-loss-sales-view-upped-2016-08-05", "https://www.nasdaq.com/articles/ligand-lgnd-q2-earnings-decline-yy-maintains-view-2016-08-05", "https://www.nasdaq.com/articles/immunogen-imgn-reports-wider-than-expected-loss-in-q4-2016-08-05", "https://www.nasdaq.com/articles/conatus-cnat-posts-narrower-q2-loss-emricasan-in-focus-2016-08-04", "https://www.nasdaq.com/articles/aerie-aeri-q2-loss-wider-than-expected-pipeline-in-focus-2016-08-04", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q2-earnings-revenues-lifts-outlook-2016-08-03", "https://www.nasdaq.com/articles/nivalis-nvls-reports-wider-than-expected-loss-in-q2-2016-08-02", "https://www.nasdaq.com/articles/integra-iart-tops-q2-earnings-grows-organically-ups-view-2016-08-01", "https://www.nasdaq.com/articles/teva-teva-beats-q2-earnings-revenues-stock-gains-2016-08-05", "https://www.nasdaq.com/articles/10-biotech-stocks-with-symptoms-of-strong-growth-2016-05-31", "https://www.nasdaq.com/articles/dont-try-beat-markets-traffic-jams-2016-05-26", "https://www.nasdaq.com/articles/ligand-lgnd-tops-q1-earnings-revenues-updates-view-2016-05-05", "https://www.nasdaq.com/articles/baxalta-bxlt-beats-on-q1-earnings-set-to-merge-with-shire-2016-04-28", "https://www.nasdaq.com/articles/bristol-myers-bmy-tops-q1-earnings-updates-2016-view-2016-04-28", "https://www.nasdaq.com/articles/celgene-celg-beats-on-q1-earnings-updates-16-outlook-2016-04-28", "https://www.nasdaq.com/articles/immunomedics-immu-catches-eye%3A-stock-moves-10.8-higher-2016-04-28", "https://www.nasdaq.com/articles/top-medical-companies-reach-high-financial-strength-2016-07-19", "https://www.nasdaq.com/articles/health-care-sector-update-04282016-adxsaniknvdq-2016-04-28", "https://www.nasdaq.com/articles/alexion-alxn-lags-q1-earnings-revenues-revises-view-2016-04-28", "https://www.nasdaq.com/articles/integra-iart-beats-on-q1-earnings-grows-organically-2016-04-28", "https://www.nasdaq.com/articles/glaxosmithkline-gsk-q1-earnings-lag-revenues-up-y-y-2016-04-28", "https://www.nasdaq.com/articles/bayer-bayry-q1-earnings-beat-estimates-retains-view-2016-04-27", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-april-27th-2016-04-27", "https://www.nasdaq.com/articles/anikas-arthritis-treatment-gains-acceptance-among-mds-and-traders-2016-04-28", "https://www.nasdaq.com/articles/top-5-stocks-with-increasing-cash-flows-2016-04-25", "https://www.nasdaq.com/articles/biogen-biib-tops-q1-earnings-slight-revenue-miss-2016-04-21", "https://www.nasdaq.com/articles/amgens-amgn-phase-iii-study-results-on-nplate-published-2016-04-20", "https://www.nasdaq.com/articles/cytori-therapeutics-cytx-shows-strength%3A-stock-up-13.2-2016-04-19", "https://www.nasdaq.com/articles/ariad-gains-on-updated-brigatinib-phase-i-ii-study-data-2016-04-18", "https://www.nasdaq.com/articles/gilead-presents-multiple-hcv-and-hbv-data-at-liver-congress-2016-04-18", "https://www.nasdaq.com/articles/edge-therapeutics-edge-in-focus%3A-stock-rises-6.7-2016-04-14", "https://www.nasdaq.com/articles/oncothyreon-onty-catches-eye%3A-stock-moves-11.6-higher-2016-04-26", "https://www.nasdaq.com/articles/horizon-pharma-plunges-on-bleak-q1-and-1h16-guidance-2016-04-13", "https://www.nasdaq.com/articles/clovis-drops-fda-panel-seeks-more-data-on-rociletinib-2016-04-13", "https://www.nasdaq.com/articles/arena-arna-gains-pain-drug-positive-in-early-stage-study-2016-04-13", "https://www.nasdaq.com/articles/gw-pharmaceuticals-begins-another-phase-iii-epidiolex-trial-2016-04-12", "https://www.nasdaq.com/articles/atyr-pharma-life-jumps%3A-stock-adds-13.1-in-session-2016-04-12", "https://www.nasdaq.com/articles/trovagene-inks-strategic-partnership-with-stratose-stock-up-2016-04-12", "https://www.nasdaq.com/articles/astrazeneca-eli-lilly-alzheimers-disease-drug-in-phase-iii-2016-04-11", "https://www.nasdaq.com/articles/repros-reveals-positive-data-on-proellex-for-uterine-fibroids-2016-04-13", "https://www.nasdaq.com/articles/clovis-hits-52-week-low-post-rociletinib-briefing-documents-2016-04-11", "https://www.nasdaq.com/articles/illumina-unveils-basespace-suite-boosts-precision-medicine-2016-04-08", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-surged-20-in-wednesday-trading-2016-04-07", "https://www.nasdaq.com/articles/clovis-oncology-clvs-catches-eye%3A-stock-moves-6-higher-2016-04-07", "https://www.nasdaq.com/articles/cytrx-corp-cytr-in-focus%3A-stock-rises-10.2-in-session-2016-04-05", "https://www.nasdaq.com/articles/glaxos-gsk-strimvelis-gets-chmp-nod-for-rare-disorder-2016-04-04", "https://www.nasdaq.com/articles/bristol-myers-gets-chmp-backing-for-opdivos-expanded-use-2016-04-04", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-moves-6.5-higher-2016-04-11", "https://www.nasdaq.com/articles/clovis-hits-52-week-low-post-rociletinib-briefing-documents-2016-04-11", "https://www.nasdaq.com/articles/illumina-unveils-basespace-suite-boosts-precision-medicine-2016-04-08", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-kanuma-gains-approval-in-japan-2016-03-29", "https://www.nasdaq.com/articles/alder-aldr-surges-on-positive-data-on-migraine-candidate-2016-03-29", "https://www.nasdaq.com/articles/pfizers-revised-filing-for-xeljanz-accepted-for-review-in-eu-2016-03-24", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-anika-therapeutics-anik-stock-2016-03-24", "https://www.nasdaq.com/articles/biodelivery-sciences-bdsi-catches-eye%3A-stock-rises-8.1-2016-03-31", "https://www.nasdaq.com/articles/jazzs-hepatic-vod-drug-defitelio-gains-fda-nod-shares-up-2016-03-31", "https://www.nasdaq.com/articles/bio-techne-buys-zephyrus-boosts-protein-platforms-division-2016-03-22", "https://www.nasdaq.com/articles/cara-therapeutics-cara-jumps%3A-stock-moves-up-21.3-2016-03-22", "https://www.nasdaq.com/articles/keryx-biopharmaceuticals-kerx-jumps%3A-stock-rises-10.1-2016-03-21", "https://www.nasdaq.com/articles/eagle-pharmaceuticals-down-on-crl-for-kangio-from-fda-2016-03-21", "https://www.nasdaq.com/articles/celgene-pfizer-present-data-from-ulcerative-colitis-trials-2016-03-21", "https://www.nasdaq.com/articles/astrazenecas-heart-drug-brilinta-disappoints-in-stroke-study-2016-03-24", "https://www.nasdaq.com/articles/mannkind-mnkd-jumps%3A-stock-adds-17.5-in-session-2016-03-18", "https://www.nasdaq.com/articles/amag-initiates-enrolment-in-phase-iii-study-on-feraheme-2016-03-17", "https://www.nasdaq.com/articles/aveo-q4-loss-narrower-than-expected-tivozanib-in-focus-2016-03-16", "https://www.nasdaq.com/articles/axsome-therapeutics-axsm-jumps%3A-stock-rises-5.7-2016-03-16", "https://www.nasdaq.com/articles/eli-lilly-down-alters-primary-endpoint-of-solanezumab-2016-03-16", "https://www.nasdaq.com/articles/repros-incurs-narrower-than-expected-loss-in-q4-shares-up-2016-03-15", "https://www.nasdaq.com/articles/inovio-ino-4q-loss-wider-than-expected-pipeline-in-focus-2016-03-15", "https://www.nasdaq.com/articles/what-is-driving-shares-of-endo-endp-sharply-lower-2016-03-18", "https://www.nasdaq.com/articles/mannkind-mnkd-jumps%3A-stock-adds-17.5-in-session-2016-03-18", "https://www.nasdaq.com/articles/should-you-get-rid-of-momenta-pharmaceuticals-mnta-now-2016-03-14", "https://www.nasdaq.com/articles/flex-pharma-flks-jumps%3A-stock-adds-16.7-in-session-2016-03-14", "https://www.nasdaq.com/articles/gileads-zydelig-under-eu-review-amid-safety-concerns-2016-03-14", "https://www.nasdaq.com/articles/pfizers-lung-cancer-drug-xalkori-label-expanded-in-u.s.-2016-03-14", "https://www.nasdaq.com/articles/biodelivery-bdsi-misses-on-earnings-and-revenue-in-q4-2016-03-11", "https://www.nasdaq.com/articles/sarepta-up-dmd-drug-eteplirsen-to-face-fda-panel-in-april-2016-03-15", "https://www.nasdaq.com/articles/prima-biomed-pbmd-jumps%3A-stock-adds-25.6-in-session-2016-03-11", "https://www.nasdaq.com/articles/spectrum-sppi-incurs-narrower-than-expected-loss-in-q4-2016-03-10", "https://www.nasdaq.com/articles/conatus-loss-narrower-than-expected-focus-on-emricasan-2016-03-10", "https://www.nasdaq.com/articles/5-stocks-to-gain-from-medical-device-excise-tax-exemption-2016-03-10", "https://www.nasdaq.com/articles/sanofi-merck-to-dissolve-joint-vaccines-venture-in-europe-2016-03-09", "https://www.nasdaq.com/articles/celldex-advised-to-discontinue-phase-iii-study-on-rintega-2016-03-08", "https://www.nasdaq.com/articles/catabasis-pharmaceuticals-catb-jumps%3A-stock-up-43.9-2016-03-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-cryolife-orthofix-international-anika-therapeutics", "https://www.nasdaq.com/articles/prima-biomed-pbmd-jumps%3A-stock-adds-25.6-in-session-2016-03-11", "https://www.nasdaq.com/articles/spectrum-sppi-incurs-narrower-than-expected-loss-in-q4-2016-03-10", "https://www.nasdaq.com/articles/conatus-loss-narrower-than-expected-focus-on-emricasan-2016-03-10", "https://www.nasdaq.com/articles/5-stocks-to-gain-from-medical-device-excise-tax-exemption-2016-03-10", "https://www.nasdaq.com/articles/baxalta-seeks-eu-approval-for-hemophilia-a-drug-adynovi-2016-03-03", "https://www.nasdaq.com/articles/nektar-nktr-reports-narrower-than-expected-q4-loss-2016-03-02", "https://www.nasdaq.com/articles/qiagen%3A-molecular-diagnostics-a-drag-currency-woes-persist-2016-03-07", "https://www.nasdaq.com/articles/amgen-seeks-fda-approval-for-blincytos-label-expansion-2016-03-02", "https://www.nasdaq.com/articles/horizon-hznp-misses-on-q4-earnings-beats-on-revenues-2016-03-01", "https://www.nasdaq.com/articles/intrexon-xon-reports-wider-q4-loss-beats-on-revenues-2016-03-01", "https://www.nasdaq.com/articles/puma-pbyi-reports-in-line-q4-loss-neratinib-in-focus-2016-03-01", "https://www.nasdaq.com/articles/asterias-biotherapeutics-ast-jumps%3A-stock-moves-up-17.9-2016-03-01", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-rises-8.3-2016-02-29", "https://www.nasdaq.com/articles/safer-small-cap-investing-puts-focus-quality-2016-02-29", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-jumps%3A-stock-rises-12.6-2016-03-02", "https://www.nasdaq.com/articles/amgen-seeks-fda-approval-for-blincytos-label-expansion-2016-03-02", "https://www.nasdaq.com/articles/qlt-qlti-reports-narrower-than-expected-loss-in-q4-2016-02-29", "https://www.nasdaq.com/articles/endo-endp-tops-q4-earnings-estimates-gives-2016-outlook-2016-02-29", "https://www.nasdaq.com/articles/bayer-bayry-q4-earnings-lag-estimates-gives-2016-view-2016-02-29", "https://www.nasdaq.com/articles/sareptas-q4-loss-wider-than-expected-eteplirsen-in-focus-2016-02-26", "https://www.nasdaq.com/articles/keryx-posts-wider-than-expected-loss-in-q4-auryxia-grows-2016-02-26", "https://www.nasdaq.com/articles/athersys-athx-worth-a-look%3A-stock-adds-7.1-in-session-2016-02-26", "https://www.nasdaq.com/articles/valeants-vrx-ceo-pearson-returns-2015-results-delayed-2016-02-29", "https://www.nasdaq.com/articles/biomarin-incurs-loss-in-q4-misses-estimates-gives-16-view-2016-02-26", "https://www.nasdaq.com/articles/radius-health-rdus-posts-wider-than-expected-loss-in-q4-2016-02-26", "https://www.nasdaq.com/articles/aegerion-q4-loss-narrower-than-expected-pipeline-in-focus-2016-02-26", "https://www.nasdaq.com/articles/alkermes-q4-loss-narrower-than-expected-updates-pipeline-2016-02-26", "https://www.nasdaq.com/articles/retrophins-re-024-granted-orphan-drug-status-in-eu-2016-02-25", "https://www.nasdaq.com/articles/jazz-tops-q4-earnings-revenues-up-y-y-gives-2016-view-2016-02-24", "https://www.nasdaq.com/articles/infinity-infi-q4-loss-narrower-than-expected-revenues-lag-2016-02-24", "https://www.nasdaq.com/articles/anika-therapeutics-anik-jumps%3A-stock-moves-up-8-2016-02-26", "https://www.nasdaq.com/articles/valeant-issues-restatement-of-financial-results-shares-down-2016-02-23", "https://www.nasdaq.com/articles/impax-q4-earnings-surpasses-expectations-revenues-beat-2016-02-23", "https://www.nasdaq.com/articles/allergan-agn-beats-on-q4-earnings-revenues-soar-y-y-2016-02-22", "https://www.nasdaq.com/articles/astrazeneca-zurampic-gets-eu-nod-brilique-label-expanded-2016-02-22", "https://www.nasdaq.com/articles/prothena-q4-loss-narrower-than-expected-pipeline-in-focus-2016-02-19", "https://www.nasdaq.com/articles/agios-agio-q4-loss-wider-than-expected-pipeline-in-focus-2016-02-19", "https://www.nasdaq.com/articles/zafgen-up-beloranib-hits-phase-iib-primary-efficacy-endpoint-2016-02-19", "https://www.nasdaq.com/articles/ariad-incurs-wider-than-expected-loss-in-q4-shares-down-2016-02-24", "https://www.nasdaq.com/articles/valeant-issues-restatement-of-financial-results-shares-down-2016-02-23", "https://www.nasdaq.com/articles/impax-q4-earnings-surpasses-expectations-revenues-beat-2016-02-23", "https://www.nasdaq.com/articles/astrazeneca-cancer-drug-gets-breakthrough-therapy-status-2016-02-18", "https://www.nasdaq.com/articles/catalyst-cprx-down-on-fdas-refusal-to-file-firdapse-nda-2016-02-18", "https://www.nasdaq.com/articles/amag-q4-earnings-revenues-up-y-y-gives-2016-outlook-2016-02-18", "https://www.nasdaq.com/articles/argos-therapeutics-args-jumps%3A-stock-rises-16.2-2016-02-17", "https://www.nasdaq.com/articles/gileads-hcv-drug-harvoni-approved-in-two-more-indications-2016-02-17", "https://www.nasdaq.com/articles/perrigo-lags-on-q4-earnings-and-revenues-updates-view-2016-02-18", "https://www.nasdaq.com/articles/repros-updates-on-proof-of-concept-study-on-enclomiphene-2016-02-17", "https://www.nasdaq.com/articles/baxalta-bxlt-beats-on-q4-earnings-set-to-merge-with-shire-2016-02-16", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-soars-on-buyout-rumors-2016-02-16", "https://www.nasdaq.com/articles/merck-mrk-gets-crl-for-zetia-vytorin-snda-from-fda-2016-02-16", "https://www.nasdaq.com/articles/amgens-aranesp-meets-primary-endpoint-in-phase-iii-study-2016-02-16", "https://www.nasdaq.com/articles/celsion-clsn-provides-pipeline-update-gen-1-in-focus-2016-02-15", "https://www.nasdaq.com/articles/clovis-clvs-rociletinib-to-face-fda-advisory-panel-in-april-2016-02-15", "https://www.nasdaq.com/articles/flexions-flxn-pain-drug-zilretta-tops-phase-iii-study-2016-02-17", "https://www.nasdaq.com/articles/repros-updates-on-proof-of-concept-study-on-enclomiphene-2016-02-17", "https://www.nasdaq.com/articles/baxalta-bxlt-beats-on-q4-earnings-set-to-merge-with-shire-2016-02-16", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-soars-on-buyout-rumors-2016-02-16", "https://www.nasdaq.com/articles/merck-mrk-gets-crl-for-zetia-vytorin-snda-from-fda-2016-02-16", "https://www.nasdaq.com/articles/amgens-aranesp-meets-primary-endpoint-in-phase-iii-study-2016-02-16", "https://www.nasdaq.com/articles/gw-pharmaceuticals-up-on-narrower-than-expected-q1-loss-2016-02-11", "https://www.nasdaq.com/articles/mylan-q4-earnings-and-revenues-lag-set-to-acquire-meda-2016-02-11", "https://www.nasdaq.com/articles/eli-lillys-alimta-gets-negative-ruling-in-uk-patent-lawsuit-2016-02-15", "https://www.nasdaq.com/articles/heat-biologics-up-as-fda-lifts-partial-hold-on-phase-ii-study-2016-02-11", "https://www.nasdaq.com/articles/sanofi-tops-q4-earnings-revenues-fall-y-y-gives-2016-view-2016-02-10", "https://www.nasdaq.com/articles/insys-insy-initiates-phase-ii-study-for-infantile-spasms-2016-02-10", "https://www.nasdaq.com/articles/seattle-genetics-sgen-q4-loss-wider-than-expected-2016-02-10", "https://www.nasdaq.com/articles/cambrex-cbm-shows-strength%3A-stock-moves-5.1-higher-2016-02-09", "https://www.nasdaq.com/articles/cytori-tanks-on-unfavorable-data-from-osteoarthritis-study-2016-02-09", "https://www.nasdaq.com/articles/epizymes-tazemetostat-gets-orphan-drug-status-in-the-u.s.-2016-02-09", "https://www.nasdaq.com/articles/kura-oncology-kura-rises%3A-stock-adds-6.8-in-session-2016-02-11", "https://www.nasdaq.com/articles/immunomedics-immu-in-focus%3A-stock-moves-20.9-higher-2016-02-08", "https://www.nasdaq.com/articles/amgens-blincyto-and-repatha-positive-in-phase-iii-studies-2016-02-05", "https://www.nasdaq.com/articles/dipexium-progresses-on-phase-iii-diabetic-foot-ulcer-studies-2016-02-05", "https://www.nasdaq.com/articles/astrazeneca-tops-q4-earnings-falls-on-bleak-2016-outlook-2016-02-05", "https://www.nasdaq.com/articles/glaxo-tops-q4-earnings-revenues-rise-y-y-2016-view-intact-2016-02-04", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-alxn-in-focus%3A-stock-rises-6.3-2016-02-04", "https://www.nasdaq.com/articles/repros-fda-meet-to-discuss-issues-of-enclomiphenes-crl-2016-02-09", "https://www.nasdaq.com/articles/sarepta-hits-52-week-low-eteplirsen-review-period-extended-2016-02-09", "https://www.nasdaq.com/articles/immunomedics-immu-in-focus%3A-stock-moves-20.9-higher-2016-02-08", "https://www.nasdaq.com/articles/amgens-blincyto-and-repatha-positive-in-phase-iii-studies-2016-02-05", "https://www.nasdaq.com/articles/sanofi-begins-search-for-vaccine-for-zika-virus-as-fear-grows-2016-02-03", "https://www.nasdaq.com/articles/myriad-genetics-tops-q2-earnings-myrisk-conversion-over-2016-02-03", "https://www.nasdaq.com/articles/argos-therapeutics-args-jumps%3A-stock-moves-up-19.6-2016-02-02", "https://www.nasdaq.com/articles/jazzs-phase-iii-data-on-defibrotide-published-in-ash-journal-2016-02-02", "https://www.nasdaq.com/articles/qiagen-q4-earnings-miss-molecular-diagnostics-disappoints-2016-02-03", "https://www.nasdaq.com/articles/prothena-prta-looks-good%3A-stock-jumps-5.1-in-session-2016-02-01", "https://www.nasdaq.com/articles/spectrum-sppi-initiates-phase-iii-study-on-spi-2012-2016-02-01", "https://www.nasdaq.com/articles/surmodics-srdx-q1-earnings-revenues-beat-estimates-2016-01-29", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-ino-jumps%3A-stock-moves-up-7.6-2016-01-29", "https://www.nasdaq.com/articles/astrazenecas-lynparza-gets-breakthrough-therapy-status-2016-01-29", "https://www.nasdaq.com/articles/mercks-hcv-drug-zepatier-gets-fda-nod-sets-lower-price-2016-01-29", "https://www.nasdaq.com/articles/exelixiss-cabozantinib-granted-priority-review-in-the-u.s.-2016-01-29", "https://www.nasdaq.com/articles/ariad-aria-to-move-ap32788-into-phase-i-ii-study-in-2q16-2016-02-02", "https://www.nasdaq.com/articles/clovis-clvs-begins-immunotherapy-combination-study-2016-01-28", "https://www.nasdaq.com/articles/argos-therapeutics-args-catches-eye%3A-stock-rises-35.9-2016-01-27", "https://www.nasdaq.com/articles/alkermes-initiates-early-stage-study-on-alzheimers-drug-2016-01-27", "https://www.nasdaq.com/articles/affimed-merck-ink-deal-for-afm13-keytruda-combination-2016-01-27", "https://www.nasdaq.com/articles/amgens-biosimilar-of-abbvies-humira-under-fda-review-2016-01-27", "https://www.nasdaq.com/articles/oncomed-tanks-on-phase-ii-pancreatic-cancer-study-update-2016-01-27", "https://www.nasdaq.com/articles/fate-fate-to-move-protmune-into-phase-i-ii-study-in-mid-16-2016-01-27", "https://www.nasdaq.com/articles/mannkind-mnkd-shows-strength%3A-stock-moves-14-higher-2016-01-28", "https://www.nasdaq.com/articles/agenus-agen-catches-eye%3A-stock-adds-8.8-in-session-2016-01-22", "https://www.nasdaq.com/articles/amgen-kyprolis-label-expanded-repatha-approved-in-japan-2016-01-22", "https://www.nasdaq.com/articles/mannkind-mnkd-signs-deal-with-receptor-life-sciences-2016-01-22", "https://www.nasdaq.com/articles/alkermes-hit-52-week-low-on-unfavorable-phase-iii-data-2016-01-22", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-in-focus%3A-stock-rises-6.7-2016-01-21", "https://www.nasdaq.com/articles/zafgen-soars-on-positive-phase-iii-efficacy-data-on-beloranib-2016-01-21", "https://www.nasdaq.com/articles/cymabay-gives-update-on-phase-iii-program-on-arhalofenate-2016-01-21", "https://www.nasdaq.com/articles/amgen-presents-encouraging-phase-iii-data-on-vectibix-2016-01-25", "https://www.nasdaq.com/articles/biotie-therapies-soars-on-%24363m-buyout-deal-with-acorda-2016-01-20", "https://www.nasdaq.com/articles/synthetic-biologics-posts-encouraging-data-on-syn-010-2016-01-20", "https://www.nasdaq.com/articles/eleven-biotherapeutics-eye-drug-fails-in-phase-iii-study-2016-01-19", "https://www.nasdaq.com/articles/heron-hrtx-down-sustol-review-period-extended-by-fda-2016-01-19", "https://www.nasdaq.com/articles/impaxs-emverm-approved-for-parasitic-worm-infestations-2016-01-19", "https://www.nasdaq.com/articles/nivalis-n91115-gets-orphan-drug-status-for-cystic-fibrosis-2016-01-18", "https://www.nasdaq.com/articles/sarepta-tanks-eteplirsen-briefing-document-raises-concerns-2016-01-18", "https://www.nasdaq.com/articles/jj-plans-to-cut-3000-medical-devices-jobs-2015-view-intact-2016-01-20", "https://www.nasdaq.com/articles/ultragenyx-pharmaceutical-rare-in-focus%3A-stock-tumbles-11.2-2016-01-14", "https://www.nasdaq.com/articles/how-anika-therapeutics-anik-stock-stands-out-in-a-strong-industry-2016-01-14", "https://www.nasdaq.com/articles/incyte-corporation-incy-in-focus%3A-stock-plunges-11-2016-01-14", "https://www.nasdaq.com/articles/ligand-emergent-biosolutions-tie-up-for-omniab-technology-2016-01-14", "https://www.nasdaq.com/articles/pluristem-psti-gets-fda-approval-for-phase-i-plx-r18-trial-2016-01-14", "https://www.nasdaq.com/articles/kite-pharma-signs-deal-with-leiden-university-medical-center-2016-01-14", "https://www.nasdaq.com/articles/horizon-hznp-ups-view-on-crealta-holdings-deal-shares-up-2016-01-13", "https://www.nasdaq.com/articles/geron-up-myelodysplastic-syndromes-phase-ii-iii-study-begins-2016-01-15", "https://www.nasdaq.com/articles/alnylam-provides-update-on-rnai-therapeutics-pipeline-2016-01-13", "https://www.nasdaq.com/articles/qiagen-q4-and-2015-preliminary-results-dim-shares-tank-13-2016-01-13", "https://www.nasdaq.com/articles/celgene-celg-drops-on-preliminary-results-2016-outlook-2016-01-12", "https://www.nasdaq.com/articles/acordas-ampyra-ends-2015-strong-note-pipeline-focus-2016-01-12", "https://www.nasdaq.com/articles/weakness-seen-in-chiasma-chma%3A-stock-slumps-16-2016-01-12", "https://www.nasdaq.com/articles/weakness-seen-in-bluebird-blue-%3A-stock-plunges-19.5-2016-01-12", "https://www.nasdaq.com/articles/surmodics-buys-normedix-for-%2414m-adjusts-2016-outlook-2016-01-12", "https://www.nasdaq.com/articles/zoetis-2016-and-2017-view-impacted-by-tax-woes-in-belgium-2016-01-13", "https://www.nasdaq.com/articles/perrigo-prgo-raises-2016-earnings-guidance-shares-up-2016-01-12", "https://www.nasdaq.com/articles/agios-agio-provides-pipeline-updates-and-2016-strategy-2016-01-12", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-january-11th-2016-01-11", "https://www.nasdaq.com/articles/uniqure-n.v.-qure-shows-strength%3A-stock-moves-up-5.3-2016-01-11", "https://www.nasdaq.com/articles/ariads-iclusig-regulatory-application-filed-in-japan-2016-01-11", "https://www.nasdaq.com/articles/sanofi-inks-multiple-deals-sarilumab-under-fda-review-2016-01-11", "https://www.nasdaq.com/articles/vertex-vrtx-gives-2016-view-orkambi-view-come-later-2016-01-11", "https://www.nasdaq.com/articles/biomarin-reveals-interim-data-from-pompe-disease-study-2016-01-12", "https://www.nasdaq.com/articles/abbvie-starts-phase-iii-program-on-abt-494-for-ra-treatment-2016-01-11", "https://www.nasdaq.com/articles/baxalta-incorporated-bxlt-jumps%3A-stock-moves-up-5.5-2016-01-05", "https://www.nasdaq.com/articles/cara-therapeutics-cara-jumps%3A-stock-moves-up-6.8-2016-01-04", "https://www.nasdaq.com/articles/sareptas-dmd-drug-eteplirsen-to-face-fda-panel-in-january-2015-12-30", "https://www.nasdaq.com/articles/anika-anik-starts-enrolment-in-phase-iii-hyalofast-study-2015-12-30", "https://www.nasdaq.com/articles/epizymes-tazemetostat-ind-application-accepted-for-dlbcl-2015-12-29", "https://www.nasdaq.com/articles/sanofis-dengue-vaccine-dengvaxia-gains-brazilian-approval-2015-12-29", "https://www.nasdaq.com/articles/integra-strong-on-international-growth-us-spine-bothers-2016-01-11", "https://www.nasdaq.com/articles/eagles-egrx-non-alcoholic-docetaxel-gets-fda-approval-2015-12-28", "https://www.nasdaq.com/articles/takeda-teva-reveal-outlook-of-japanese-business-venture-2015-12-28", "https://www.nasdaq.com/articles/sanofi-seeks-fda-approval-for-diabetes-drug-combination-2015-12-28", "https://www.nasdaq.com/articles/agenus-acquires-phosimmune-adds-cancer-neoantigens-2015-12-28", "https://www.nasdaq.com/articles/argos-therapeutics-args-catches-eye%3A-stock-rises-6.4-2015-12-24", "https://www.nasdaq.com/articles/merrimack-alters-endpoint-in-cancer-drug-trial-raises-funds-2015-12-23", "https://www.nasdaq.com/articles/pfizer-merck-kgaa-start-two-phase-iii-studies-on-avelumab-2015-12-23", "https://www.nasdaq.com/articles/evogene-evgn-shows-strength%3A-stock-moves-up-9-2015-12-28", "https://www.nasdaq.com/articles/celyads-c-cure-ind-authorized-in-u.s.-for-phase-iii-study-2015-12-23", "https://www.nasdaq.com/articles/actelions-uptravi-approved-in-the-u.s.-for-pah-treatment-2015-12-23", "https://www.nasdaq.com/articles/should-you-dump-cardiovascular-systems-csii-now-2015-12-23", "https://www.nasdaq.com/articles/baxaltas-adynovate-positive-in-phase-iii-pediatric-study-2015-12-22", "https://www.nasdaq.com/articles/repros-provides-update-on-proellex-program-data-by-3q16-2015-12-22", "https://www.nasdaq.com/articles/alnylam-submits-clinical-trial-application-for-aln-go1-in-uk-2015-12-22", "https://www.nasdaq.com/articles/aduro-doses-first-patient-in-phase-i-study-on-adu-741-2015-12-22", "https://www.nasdaq.com/articles/astrazenecas-zurampic-fda-approved-with-boxed-warning-2015-12-23", "https://www.nasdaq.com/articles/atara-biotherapeutics-atra-jumps%3A-stock-moves-up-6-2015-12-21", "https://www.nasdaq.com/articles/astrazeneca-updates-on-durvalumab-chmp-favors-3-drugs-2015-12-21", "https://www.nasdaq.com/articles/atyr-pharma-life-jumps%3A-stock-moves-18.8-higher-2015-12-18", "https://www.nasdaq.com/articles/intercept-icpt-down-on-delay-in-fdas-verdict-on-lead-drug-2015-12-18", "https://www.nasdaq.com/articles/alnylam-initiates-final-part-of-phase-i-ii-study-on-aln-cc5-2015-12-18", "https://www.nasdaq.com/articles/array-biopharma-arry-jumps%3A-stock-moves-up-20.6-2015-12-17", "https://www.nasdaq.com/articles/alkermes-hits-52-week-high-on-pipeline-update-aristada-2015-12-17", "https://www.nasdaq.com/articles/myriad-genetics%3A-test-expansion-strong-currency-woes-linger-2015-12-22", "https://www.nasdaq.com/articles/atara-biotherapeutics-atra-jumps%3A-stock-moves-up-6-2015-12-21", "https://www.nasdaq.com/articles/astrazeneca-updates-on-durvalumab-chmp-favors-3-drugs-2015-12-21", "https://www.nasdaq.com/articles/atara-plunges-on-poor-results-from-phase-ii-pinta-745-study-2015-12-15", "https://www.nasdaq.com/articles/horizon-hznp-to-acquire-crealta-holdings-in-a-%24510m-deal-2015-12-14", "https://www.nasdaq.com/articles/otonomys-ear-infection-drug-otiprio-approved-in-the-u.s.-2015-12-14", "https://www.nasdaq.com/articles/ariad-lowers-iclusigs-2015-revenue-outlook-shares-fall-2015-12-14", "https://www.nasdaq.com/articles/evotec-spero-deal-extended-for-gram-negative-bacteria-2015-12-16", "https://www.nasdaq.com/articles/raptor-reports-efficacy-data-from-cyst-hd-study-on-rp103-2015-12-11", "https://www.nasdaq.com/articles/sanofis-dengue-vaccine-dengvaxia-gets-mexican-approval-2015-12-10", "https://www.nasdaq.com/articles/oncogenex-to-continue-with-borealis-2-study-on-apatorsen-2015-12-10", "https://www.nasdaq.com/articles/pfizer-merck-kgaa-begin-two-phase-iii-studies-on-avelumab-2015-12-10", "https://www.nasdaq.com/articles/gilead-reveals-encouraging-data-on-leukemia-drug-zydelig-2015-12-10", "https://www.nasdaq.com/articles/proqr-therapeutics-prqr-rises%3A-stock-up-6.1-in-session-2015-12-09", "https://www.nasdaq.com/articles/cara-therapeutics-cara-jumps%3A-stock-moves-up-10.2-2015-12-09", "https://www.nasdaq.com/articles/caladrius-biosciences-clbs-jumps%3A-stock-moves-up-6.5-2015-12-11", "https://www.nasdaq.com/articles/alexion-alxn-gains-after-kanuma-receives-fda-approval-2015-12-09", "https://www.nasdaq.com/articles/should-you-retain-integra-lifesciences-iart-in-your-portfolio-2015-12-09", "https://www.nasdaq.com/articles/gw-pharmaceuticals-posts-narrower-than-expected-q4-loss-2015-12-08", "https://www.nasdaq.com/articles/stemline-therapeutics-stml-jumps%3A-stock-moves-up-5.6-2015-12-08", "https://www.nasdaq.com/articles/kite-pharma-begins-study-on-kte-c19-presents-data-at-ash-2015-12-08", "https://www.nasdaq.com/articles/celgene-astrazeneca-start-immuno-oncology-drug-studies-2015-12-08", "https://www.nasdaq.com/articles/bluebird-bio-crashes-after-clinical-trial-update-2015-12-07", "https://www.nasdaq.com/articles/baxaltas-vonvendi-gets-fda-nod-for-von-willebrand-disease-2015-12-09", "https://www.nasdaq.com/articles/alexion-alxn-gains-after-kanuma-receives-fda-approval-2015-12-09", "https://www.nasdaq.com/articles/should-you-retain-integra-lifesciences-iart-in-your-portfolio-2015-12-09", "https://www.nasdaq.com/articles/cytori-reports-positive-top-line-data-on-eccs-50-yet-again-2015-12-03", "https://www.nasdaq.com/articles/baxalta-wins-chmp-backing-for-sanquin-to-start-production-2015-12-03", "https://www.nasdaq.com/articles/anika-anik%3A-moving-average-crossover-alert-2015-12-02", "https://www.nasdaq.com/articles/synthetic-syn-unveils-positive-phase-iib-data-on-syn-004-2015-12-02", "https://www.nasdaq.com/articles/repros-hits-52-week-low-after-enclomiphene-receives-crl-2015-12-02", "https://www.nasdaq.com/articles/should-you-dump-illumina-ilmn-from-your-portfolio-now-2015-12-07", "https://www.nasdaq.com/articles/puma-pbyi-updates-on-neratinibs-progress-in-europe-2015-12-01", "https://www.nasdaq.com/articles/horizons-hznp-ravicti-okd-in-eu-for-urea-cycle-disorders-2015-12-01", "https://www.nasdaq.com/articles/intercept-icpt-initiates-study-on-another-bile-acid-analog-2015-12-01", "https://www.nasdaq.com/articles/why-anika-therapeutics-anik-stock-might-be-a-great-pick-2015-11-30", "https://www.nasdaq.com/articles/kalobios-surges-30-martin-shkreli-stops-lending-shares-2015-11-30", "https://www.nasdaq.com/articles/impaxs-parkinsons-disease-drug-numient-approved-in-eu-2015-11-26", "https://www.nasdaq.com/articles/ocular-begins-second-phase-iii-allergic-conjunctivitis-study-2015-11-26", "https://www.nasdaq.com/articles/axovant-sciences-axon-jumps%3A-stock-moves-up-9.8-2015-12-01", "https://www.nasdaq.com/articles/eli-lillys-portrazza-gets-fda-nod-carries-boxed-warning-2015-11-25", "https://www.nasdaq.com/articles/biomarins-vimizim-gets-nice-recommendation-in-england-2015-11-24", "https://www.nasdaq.com/articles/why-anika-therapeutics-anik-could-be-positioned-for-a-surge-2015-11-24", "https://www.nasdaq.com/articles/synthetic-biologics-syn-rises%3A-stock-adds-11-in-session-2015-11-24", "https://www.nasdaq.com/articles/amag-responds-to-fdas-crl-for-single-dose-vial-of-makena-2015-11-24", "https://www.nasdaq.com/articles/biomarin-down-on-fdas-briefing-document-on-kyndrisa-2015-11-23", "https://www.nasdaq.com/articles/astrazeneca-sanofi-to-swap-210000-chemical-compounds-2015-11-23", "https://www.nasdaq.com/articles/peregrine-pharmaceuticals-pphm-jumps%3A-stock-up-6.1-2015-11-25", "https://www.nasdaq.com/articles/surmodics-buys-balloon-catheter-maker-creagh-medical-2015-11-23", "https://www.nasdaq.com/articles/amgens-multiple-myeloma-drug-kyprolis-gains-eu-approval-2015-11-20", "https://www.nasdaq.com/articles/aduro-adro-creates-subsidiary-aduro-biotech-europe-2015-11-20", "https://www.nasdaq.com/articles/global-blood-therapeutics-gbt-jumps%3A-stock-up-16.7-2015-11-19", "https://www.nasdaq.com/articles/amag-receives-another-crl-for-single-dose-vial-of-makena-2015-11-19", "https://www.nasdaq.com/articles/spectrum-sppi-up-on-selling-zevalin-rights-to-mundipharma-2015-11-19", "https://www.nasdaq.com/articles/protalix-meets-fda-to-start-phase-iii-fabry-disease-study-2015-11-17", "https://www.nasdaq.com/articles/celldex-jumps-on-phase-ii-overall-survival-data-on-rintega-2015-11-23", "https://www.nasdaq.com/articles/array-arry-pierre-fabre-collaborate-for-cancer-drugs-2015-11-17", "https://www.nasdaq.com/articles/looking-for-a-top-momentum-stock-3-reasons-why-anika-therapeutics-anik-is-a-great-choice", "https://www.nasdaq.com/articles/repros-provides-update-on-phase-iib-study-on-proellex-2015-11-13", "https://www.nasdaq.com/articles/illumina-ilmn-set-to-enter-the-coveted-sp-500-stock-up-2015-11-13", "https://www.nasdaq.com/articles/genomic-health-overseas-business-strong-margin-woes-stay-2015-11-11", "https://www.nasdaq.com/articles/catalyst-pharmaceuticals-q3-loss-narrower-than-expected-2015-11-10", "https://www.nasdaq.com/articles/repros-q3-loss-narrower-than-expected-pipeline-in-focus-2015-11-10", "https://www.nasdaq.com/articles/clovis-crashes-70-fda-seeks-more-data-on-rociletinib-2015-11-17", "https://www.nasdaq.com/articles/biodelivery-bdsi-down-on-wider-than-expected-q3-loss-2015-11-10", "https://www.nasdaq.com/articles/intrexon-xon-reports-wider-than-expected-loss-in-q3-2015-11-10", "https://www.nasdaq.com/articles/puma-biotechnology-reports-wider-than-expected-q3-loss-2015-11-10", "https://www.nasdaq.com/articles/trovagene-rallies-despite-wider-than-expected-q3-loss-2015-11-10", "https://www.nasdaq.com/articles/merrimack-mack-reports-narrower-than-expected-q3-loss-2015-11-10", "https://www.nasdaq.com/articles/clovis-posts-wider-than-expected-loss-in-q3-shares-down-2015-11-09", "https://www.nasdaq.com/articles/horizon-hznp-up-on-q3-earnings-beat-raises-guidance-2015-11-09", "https://www.nasdaq.com/articles/aveo-aveo-swings-into-earnings-in-q3-revenues-up-y-y-2015-11-10", "https://www.nasdaq.com/articles/emergent-biosolutions-tops-q3-earnings-and-revenues-2015-11-06", "https://www.nasdaq.com/articles/nektar-nktr-reports-narrower-than-expected-q3-loss-2015-11-06", "https://www.nasdaq.com/articles/synta-q3-loss-narrower-than-expected-to-cut-jobs-by-60-2015-11-06", "https://www.nasdaq.com/articles/agios-agio-q3-loss-wider-than-expected-pipeline-in-focus-2015-11-06", "https://www.nasdaq.com/articles/gileads-gild-cocktail-hiv-drug-genvoya-gets-fda-nod-2015-11-06", "https://www.nasdaq.com/articles/conatus-posts-wider-than-expected-loss-emricasan-in-focus-2015-11-05", "https://www.nasdaq.com/articles/celgene-tops-q3-earnings-keeps-2015-bottom-line-view-2015-11-05", "https://www.nasdaq.com/articles/dr.-reddys-rdy-receives-fda-warning-letter-shares-fall-2015-11-09", "https://www.nasdaq.com/articles/myriad-genetics-tops-q1-earnings-revenues-keeps-15-view-2015-11-04", "https://www.nasdaq.com/articles/henry-schein-tops-q3-earnings-revenues-tweaks-15-view-2015-11-04", "https://www.nasdaq.com/articles/genomic-health-q3-loss-wider-than-expected-15-view-kept-2015-11-04", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q3-earnings-revenues-view-up-2015-11-04", "https://www.nasdaq.com/articles/portolas-phase-iii-study-on-betrixaban-completes-enrollment-2015-11-02", "https://www.nasdaq.com/articles/qlt-qlti-reports-narrower-than-expected-loss-in-q3-2015-10-30", "https://www.nasdaq.com/articles/bayer-bayry-q3-revenues-up-y-y-2015-view-adjusted-2015-10-30", "https://www.nasdaq.com/articles/gileads-sovaldi-in-focus-on-bradyarrhythmia-concerns-2015-11-05", "https://www.nasdaq.com/articles/strength-seen-in-anika-therapeutics-anik%3A-stock-up-7.1-2015-10-30", "https://www.nasdaq.com/articles/mylan-tops-q3-earnings-misses-revenues-updates-view-2015-10-30", "https://www.nasdaq.com/articles/alexion-beats-on-earnings-in-q3-but-misses-on-revenues-2015-10-29", "https://www.nasdaq.com/articles/qiagen-misses-on-q3-earnings-and-revenues-liquidity-strong-2015-10-29", "https://www.nasdaq.com/articles/amag-to-initiate-head-to-head-phase-iii-study-on-feraheme-2015-10-29", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q3-earnings-hcv-drugs-lose-shine-2015-10-28", "https://www.nasdaq.com/articles/trimble-navigations-trmb-q3-earnings%3A-what-lies-ahead-2015-10-28", "https://www.nasdaq.com/articles/gnc-holdings-earnings-revenues-lag-franchise-unit-strong-2015-10-30", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q3-earnings%3A-what-to-expect-2015-10-27", "https://www.nasdaq.com/articles/what-awaits-biomarin-bmrn-this-earnings-season-2015-10-27", "https://www.nasdaq.com/articles/biodelivery-endo-up-on-fda-approval-of-pain-drug-belbuca-2015-10-27", "https://www.nasdaq.com/articles/te-connectivity-tel-q4-earnings-likely-to-disappoint-2015-10-26", "https://www.nasdaq.com/articles/gopro-gpro-preview%3A-can-it-pull-an-earnings-surprise-2015-10-26", "https://www.nasdaq.com/articles/will-macroeconomic-woes-hurt-flir-systems-q3-earnings-2015-10-26", "https://www.nasdaq.com/articles/can-alliance-fiber-afop-earnings-pull-a-surprise-in-q3-2015-10-26", "https://www.nasdaq.com/articles/bristol-myers-beats-on-q3-earnings-guidance-encouraging-2015-10-27", "https://www.nasdaq.com/articles/will-ingersoll-ir-q3-earnings-disappoint-this-season-2015-10-23", "https://www.nasdaq.com/articles/waste-management-wm-q3-earnings%3A-what-to-expect-2015-10-23", "https://www.nasdaq.com/articles/will-the-earnings-streak-continue-for-vasco-vdsi-in-q3-2015-10-23", "https://www.nasdaq.com/articles/can-bristol-myers-bmy-sustain-earnings-momentum-in-q3-2015-10-23", "https://www.nasdaq.com/articles/whats-in-store-for-gilead-gild-this-earnings-season-2015-10-23", "https://www.nasdaq.com/articles/can-broadcom-brcm-surprise-on-q3-earnings-this-time-2015-10-23", "https://www.nasdaq.com/articles/synta-falls-stops-ganetespib-late-stage-lung-cancer-study-2015-10-23", "https://www.nasdaq.com/articles/foamix-starts-patient-enrollment-in-phase-ii-study-on-fmx103-2015-10-23", "https://www.nasdaq.com/articles/illumina-tops-q3-earnings-meets-revenues-15-view-cut-2015-10-21", "https://www.nasdaq.com/articles/will-generic-segment-drive-perrigo-prgo-q3-earnings-beat-2015-10-21", "https://www.nasdaq.com/articles/what-to-expect-from-overstock.coms-ostk-q3-earnings-2015-10-21", "https://www.nasdaq.com/articles/cypress-semiconductor-cy-q3-earnings%3A-whats-in-store-2015-10-20", "https://www.nasdaq.com/articles/texas-instruments-txn-q3-earnings%3A-what-to-expect-2015-10-19", "https://www.nasdaq.com/articles/biomarins-drisapersen-to-be-reviewed-by-fdas-committee-2015-10-19", "https://www.nasdaq.com/articles/zafgen-continues-to-fall-partial-clinical-hold-on-beloranib-2015-10-19", "https://www.nasdaq.com/articles/ebays-ebay-1st-earnings-without-paypal%3A-whats-in-store-revised-2015-10-23", "https://www.nasdaq.com/articles/will-hubbell-hub-b-disappoint-earnings-estimates-in-q3-2015-10-19", "https://www.nasdaq.com/articles/cms-hikes-medicare-rate-for-genomics-breast-cancer-test-revised-2015-10-16", "https://www.nasdaq.com/articles/will-nielsens-nlsn-earnings-disappoint-estimates-in-q3-2015-10-16", "https://www.nasdaq.com/articles/medicare-initiates-coverage-on-genomic-prostate-cancer-test-2015-10-16", "https://www.nasdaq.com/articles/what-to-expect-from-lam-researchs-lrcx-q1-earnings-2015-10-16", "https://www.nasdaq.com/articles/ebays-ebay-1st-earnings-without-paypal%3A-whats-in-store-2015-10-16", "https://www.nasdaq.com/articles/will-nielsens-nlsn-earnings-disappoint-estimates-in-q3-2015-10-16-0", "https://www.nasdaq.com/articles/whats-in-store-for-morningstar-morn-in-q3-earnings-2015-10-19", "https://www.nasdaq.com/articles/alnylam-offers-data-on-aln-ttrsc02-platform-technology-2015-10-15", "https://www.nasdaq.com/articles/zafgen-reports-patient-death-in-late-stage-beloranib-study-2015-10-15", "https://www.nasdaq.com/articles/aimmune-therapeutics-aimt-jumps%3A-stock-rises-13.7-2015-10-14", "https://www.nasdaq.com/articles/incyte-merck-expand-melanoma-treatment-collaboration-2015-10-14", "https://www.nasdaq.com/articles/theravance-tbph-advances-td-0714-submits-ind-to-fda-2015-10-14", "https://www.nasdaq.com/articles/xenoport-xnpt-shows-strength%3A-stock-moves-up-9.3-2015-10-13", "https://www.nasdaq.com/articles/biomarin-presents-data-on-vosoritide-at-medical-meeting-2015-10-13", "https://www.nasdaq.com/articles/portolas-betrixaban-gets-fast-track-designation-in-the-u.s.-2015-10-15", "https://www.nasdaq.com/articles/alexion-alxn-presents-positive-5-year-data-on-strensiq-2015-10-13", "https://www.nasdaq.com/articles/cms-hikes-medicare-rate-for-genomics-breast-cancer-test-2015-10-13", "https://www.nasdaq.com/articles/dyax-corp.-dyax-catches-eye%3A-stock-adds-7.3-in-session-2015-10-12", "https://www.nasdaq.com/articles/bristol-myers-cancer-drug-opdivos-label-expanded-in-u.s.-2015-10-12", "https://www.nasdaq.com/articles/radius-rdus-reports-positive-data-on-osteoporosis-drug-2015-10-12", "https://www.nasdaq.com/articles/galapagos-glpg-reports-positive-data-on-glpg1837-2015-10-12", "https://www.nasdaq.com/articles/qiagen-poised-on-molecular-diagnostics-international-business-2015-10-12", "https://www.nasdaq.com/articles/celgene-celg-posts-encouraging-one-year-data-on-otezla-2015-10-13", "https://www.nasdaq.com/articles/alnylam-initiates-extension-study-on-aln-at3-for-hemophilia-2015-10-09", "https://www.nasdaq.com/articles/verastem-vstm-shows-strength%3A-stock-moves-up-15.2-2015-10-08", "https://www.nasdaq.com/articles/acelrx-updates-on-zalviso-for-pain-management-treatment-2015-10-08", "https://www.nasdaq.com/articles/gtx-gtxi-shows-strength%3A-stock-adds-37.8-in-session-2015-10-07", "https://www.nasdaq.com/articles/infinity-infi-updates-on-duvelisib-and-ipi-549-on-rd-day-2015-10-07", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-in-focus%3A-stock-surges-10.5-2015-10-06", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-moves-up-12-2015-10-06", "https://www.nasdaq.com/articles/aduro-gets-milestone-payment-for-adu-214s-ind-submission-2015-10-09", "https://www.nasdaq.com/articles/mercks-mrk-keytruda-gains-fda-nod-for-label-expansion-2015-10-05", "https://www.nasdaq.com/articles/oncomed-pharmaceuticals-omed-rises%3A-stock-gains-13-2015-10-05", "https://www.nasdaq.com/articles/incyte-incy-shows-strength%3A-stock-adds-7.2-in-session-2015-10-05", "https://www.nasdaq.com/articles/illumina-poised-on-product-innovation-global-expansion-2015-10-05", "https://www.nasdaq.com/articles/bristol-myers-melanoma-combo-opdivo-yervoy-gets-fda-nod-2015-10-02", "https://www.nasdaq.com/articles/illumina-downgraded-by-leerink-shares-plummet-over-10-2015-10-02", "https://www.nasdaq.com/articles/integra-iart-hopeful-on-spine-spin-off-amid-global-woes-2015-10-02", "https://www.nasdaq.com/articles/illumina-ilmn-shares-tumble-on-weak-outlook-for-sales-2015-10-06", "https://www.nasdaq.com/articles/cara-therapeutics-cara-jumps%3A-stock-moves-up-16.6-2015-10-01", "https://www.nasdaq.com/articles/infinity-infi-up-set-to-get-duvelisib-milestone-payment-2015-10-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-express-scripts-abbvie-amgen-anika-therapeutics-and-pdl", "https://www.nasdaq.com/articles/lexicon-presents-positive-data-from-telotristat-etiprate-study-2015-09-30", "https://www.nasdaq.com/articles/anika-therapeutics-anik-is-in-oversold-territory%3A-whats-next-2015-09-29", "https://www.nasdaq.com/articles/weakness-seen-in-bluebird-blue%3A-stock-tumbles-13.3-2015-09-29", "https://www.nasdaq.com/articles/endo-completes-%248.05b-par-pharma-acquisition-updates-view-2015-09-29", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-october-1st-2015-10-01", "https://www.nasdaq.com/articles/health-care-sector-update-08282015-nvo-ghdx-anik-2015-08-28", "https://www.nasdaq.com/articles/anika-stock%3A-what-is-the-social-media-crowd-thinking-about-anik-2015-08-27", "https://www.nasdaq.com/articles/why-anika-therapeutics-gained-13-july-2015-08-07", "https://www.nasdaq.com/articles/commit-buy-anika-therapeutics-30-earn-67-annualized-using-options-2014-12-10", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2014-12-10", "https://www.nasdaq.com/articles/commit-purchase-anika-therapeutics-35-earn-103-annualized-using-options-2014-05-22", "https://www.nasdaq.com/articles/mid-day-market-update-first-solar-falls-downbeat-results-anika-therapeutics-shares-jump", "https://www.nasdaq.com/articles/anika-therapeutics-stock%3A-3-reasons-why-anik-is-a-top-choice-for-value-investors-2015-09", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-08-14", "https://www.nasdaq.com/articles/supernus-files-patent-infringement-lawsuit-analyst-blog-2013-08-09", "https://www.nasdaq.com/articles/mdco-acquires-profibrix-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/data-on-biolinerx-bl-8040-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/osiris-loss-wider-than-expected-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-avanir-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-pacira-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-lowes-q4-profit-surges-63-2014-02-26", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-08-14", "https://www.nasdaq.com/articles/loss-narrows-at-dynavax-in-q2-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/davita-and-myriad-join-forces-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/data-on-astex-candidate-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/good-news-for-celgenes-revlimid-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/amgen-xgeva-label-expanded-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/paciras-exparel-disappoints-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/celg-presents-positive-long-term-data-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/xenon-licenses-isis-drug-analyst-blog-2013-06-11", "https://www.nasdaq.com/articles/dynavax-down-on-heplisav-delay-analyst-blog-2013-06-11", "https://www.nasdaq.com/articles/sgen-starts-adcetris-phase-i-ii-study-analyst-blog-2013-06-11", "https://www.nasdaq.com/articles/encouraging-data-on-alexions-soliris-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/priority-review-for-gilead-drug-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/encouraging-data-on-isis-candidate-analyst-blog-2013-06-06", "https://www.nasdaq.com/articles/myriad%3A-end-to-legal-battle-over-patents-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/the-medicines-co.-inks-deal-with-profibrix-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/fda-issues-warning-letter-to-novartis-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/setback-for-pluristem-therapeutics-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/canada-nod-for-medivations-xtandi-analyst-blog-2013-06-04", "https://www.nasdaq.com/articles/roche-presents-data-on-avastin-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/chmp-positive-on-tevas-lonquex-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/biogen-delays-eu-launch-of-tecfidera-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/astellas-tecnofarma-in-distribution-deal-analyst-blog-2013-06-06", "https://www.nasdaq.com/articles/encouraging-news-for-peregrine-pharma-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/new-diagnostic-solution-from-roche-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/promising-data-on-oncys-reolysin-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/encouraging-news-for-peregrine-pharma-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/biogen-submits-plegridy-bla-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/xenoport-candidate-disappoints-analyst-blog-2013-05-21", "https://www.nasdaq.com/articles/biogens-hemophilia-bla-accepted-analyst-blog-2013-05-20", "https://www.nasdaq.com/articles/medivation-astellas-seek-xtandi-approval-in-japan-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/pediatric-approval-for-mdco-bmys-recothrom-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/amgen-to-set-up-jv-in-china-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/disappointing-1q-earnings-for-iart-analyst-blog-2013-05-10", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-dynavax-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-thursday-tale-of-the-tape-2013-05-02", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-anik-gild-petm-nke-adbe-2013-03-31", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-monday-tale-of-the-tape-2012-06-04", "https://www.nasdaq.com/articles/sgens-adcetris-under-fda-review-analyst-blog-2013-05-16", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-friday-tale-of-the-tape-2012-05-25", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-wednesday-tale-of-the-tape-2012-05-23", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-thursday-tale-of-the-tape-2012-05-17", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-thursday-tale-of-the-tape-2012-05-10", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-tuesday-tale-of-the-tape-2012-05-08", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-wednesday-tale-of-the-tape-2012-04-25", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-friday-tale-of-the-tape-2012-04-20", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-wednesday-tale-of-the-tape-2012-05-30", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-monday-tale-of-the-tape-2012-04-16", "https://www.nasdaq.com/articles/stocks-down-mid-day-lows-investors-digest-mixed-economic-data-2011-02-15", "https://www.nasdaq.com/articles/mid-day-update-stocks-down-economic-data-investors-eye-nyse-deutsche-boerse-deal-2011-02", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-wednesday-tale-of-the-tape-2012-04-18"], "Content": []}